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Abstract 
L-3,4-dihydroxyphenylalanine (L-DOPA) can ease symptoms of Parkinson’s disease (PD), but
extended use of L-DOPA causes abnormal involuntary movements (AIMs) called L-DOPA induced 
dyskinesias (LIDs). The present study aims to investigate alterations in HPA axis stimulation, 
neuroinflammation, DA signalling, and cholinergic signalling using molecular markers in a rat model 
of LIDs. A unilateral 6-hydroxydopamine (6-OHDA) lesion in the medial forebrain bundle of male 
Sprague-Dawley rats was used to model Parkinsonism. The PD rat model was treated with L-DOPA to 
further model LIDs. L-DOPA treated groups included rodents treated for 14 days and rats that 
developed AIMs during 28 days of treatment. LIDs severity was rated using the AIMs score.  Motor 
skills were assessed using the elevated beam walking test. Cognitive functions were assessed using the 
Morris water maze test and the novel object recognition test. The concentrations of tumour necrosis 
factor-alpha (TNF-α), corticosterone, acetylcholinesterase (AChE), and dopamine (DA), and the 
expressions of D1 receptor (D1R) and D2 receptor (D2R) were quantified. L-DOPA treatment for 14 
days improved the 6-OHDA-induced hypokinesia, incoordination, spatial learning, and spatial memory 
but did not improve recognition memory impairment. Prolonged (28 days) L-DOPA treatment led to 
AIMs development and failed to improve 6-OHDA-induced spatial memory impairment. L-DOPA 
treatment significantly increased striatal TNF-α and striatal DA concentration, cerebellar TNF-α and 
DA concentration, prefrontal cortex (PFC) DA and AChE concentration, but significantly reduced 
striatal AChE concentration, the concentration of TNF-α and D1R expression in the PFC, plasma 
corticosterone, and hippocampal AChE concentration. When treatment was prolonged for 28 days, 
striatal D2R expression significantly increased, while cerebellar TNF-α and DA concentration 
significantly decreased. Increased striatal D2R signalling increases motor output since the direct basal 
ganglia (BG) pathway is activated in LIDs. The present study showed significantly increased cerebellar 
DA concentration in response to BG hypoactivity; however, as striatal D2R increased cerebellar DA 
decreased. The connectivity between the BG and cerebellum in PD increases off L-DOPA and lowers 
On L-DOPA. The cognitive decline in the 6-OHDA lesioned rodents and those treated with L-DOPA 
results from increased AChE concentration. High AChE concentration leads to increased ACh 
catabolism which impairs cognitive function. 
Keywords: Parkinson’s disease, L-3,4-dihydroxyphenylalanine, Dopamine, tumour necrosis factor-
alpha, acetylcholinesterase, corticosterone  
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Chapter 1: Literature review 
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative motor disorder, that results from a dysregulation in the 
basal ganglia (BG) (Boecker et al., 1999). This disease results from the death of dopamine (DA) neurons 
in the pars compacta of the substantia nigra, and this deficiency of DA signalling in the BG leads to 
motor symptoms characteristic of PD (Fearnley and Lees, 1991, Gibb and Lees, 1991). The motor 
symptoms used to diagnose PD include bradykinesia, akinesia, resting tremors, postural instability, and 
rigidity (Hughes et al., 1992, Jankovic and Tolosa, 2007, Postuma et al., 2015). PD affects 1-2 people 
in a population of 1000, affecting most people above the age of 60 years (Tysnes and Storstein, 2017). 
Approximately 10% of PD patients in the early, untreated disease state met the traditional cognitive 
impairment criteria (Weintraub and Claassen, 2017).  
The cognitive deficits expressed by PD patients include impaired visuospatial learning, spatial 
recognition memory, attention deficiencies and others (Chaudhuri et al., 2006, Amboni et al., 2015, 
Pfeiffer, 2016). The cognitive deficits in PD may result from irregular dopaminergic, noradrenergic, 
and cholinergic inputs to the cortex (Bäckström et al., 2018). DA deficiency in PD is related to mild 
cognitive deficits in frontostriatal functions, memory and attention deficits prevalent in PD (Bäckström 
et al., 2018). The most effective pharmacotherapy for PD is L-3,4-dihydroxyphenylalanine (L-DOPA) 
combined with monoamine oxidase and catechol-O-methyltransferase inhibitors (Kang et al., 2016). L-
DOPA is a DA precursor molecule that can cross the blood-brain barrier, and the inhibitors reduce the 
peripheral degradation of L-DOPA, therefore increasing DA signalling in the brain (Ruonala et al., 
2018).  
Long-term use of L-DOPA results in abnormal involuntary movements called levodopa-induced 
dyskinesias (LIDs) (Luquin et al., 1992). LIDs affect 40% of PD patients that have been treated with L-
DOPA for six years, and this percentage surges to 60% after ten years of treatment (Ahlskog and 
Muenter, 2001, Tran et al., 2018). Studies to elucidate the pathophysiology of LIDs have shown the 
involvement of oxidative stress, dysregulated serotonin signalling, dysregulated DA signalling, 
dysregulated cholinergic signalling, dysfunction of the glutamatergic pathway, dysfunction of the 
GABAergic pathway and others (Murer et al., 1998, Shen et al., 2015, Ndlovu et al., 2016, Smith et al., 
2016).  These molecular dysregulations in brain areas, like those of the basal ganglia, can lead to 
abnormal involuntary movements in PD patients treated with L-DOPA (Ndlovu et al., 2016). However, 




Molecular dysfunctions in LIDs were studied using animal models (Branchi et al., 2008, Tadaiesky et 
al., 2008). Numerous animal models of PD were modified to model dyskinesias that result from treating 
parkinsonism with L-DOPA over a specified period (Jackson et al., 2014, Iderberg et al., 2015, Ndlovu 
et al., 2016). Models that use neurotoxins like 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) 
or 6‐hydroxydopamine (6-OHDA) are used if a nigrostriatal lesion is required for the study (Calne et 
al., 1985, Mandel et al., 1997). The unilateral lesion into the medial forebrain bundle (MFB) has been 
shown to induce memory impairments showing that DA depletion may play a role in the cognitive 
decline evident in PD (Tadaiesky et al., 2008). The lesion in the MFB is thought to reduce DA signalling 
in the striatum, prefrontal cortex (PFC), and hippocampus, which are brain areas that play a crucial role 
in cognition (Du et al., 2018). The lesion in the nigrostriatal pathway affects the BG pathway, 
contributing to the initiation of the desired movement and inhibition of undesired movement 
(Ungerstedt, 1968, Middleton and Strick, 1994). 
2. The Basal Ganglia pathway and symptoms of Parkinson’s disease 
The basal ganglia (BG) comprises subcortical nuclei that span the telencephalon, midbrain and 
diencephalon (Albin et al., 1989). The nuclei that make up the BG include the striatum, substantia nigra 
(the pars compacta and the pars reticulata), the Globus pallidus (the internal and the external segment), 
and the subthalamic nucleus (figure 1a) (Heimer, 1983, Rommelfanger and Wichmann, 2010). 
Dopamine (DA) is known for modulating the functions of the BG, and the disrupted DA signalling in 
the striatum and other areas is thought to play a significant role in the development of symptoms of 
Parkinson’s disease (PD) (Sian et al., 1994, Ruskin et al., 1999, Szewczyk-Krolikowski et al., 2016). 
The BG dysregulation can be attributed to the death of dopaminergic neurons in the pars compacta of 
the substantia nigra (figure1b), which supplies the BG, specifically the striatum, with DA (Hajdu et al., 
1973, Burns et al., 1983). Motor symptoms of PD become apparent when the concentration of DA in 
the striatum is low (Zarow et al., 2003). The striatum projects to the substantia nigra par reticulata and 
the outer segment of the Globus pallidus (figure 1a), and therefore plays a crucial role in both the direct 
and indirect basal ganglia pathways (Domesick et al., 1983, Staines and Fibiger, 1984). The classical 
PD model implies that the degeneration of the DA neurons (figure 1b) results in hyperactivity of the 
neurons in the striatum (Albin et al., 1989). This leads to uncurbed inhibition of the neurons of the outer 
segment of the Globus pallidus and, therefore, a reduced inhibitory tone of the subthalamic nucleus 
(Starr et al., 2005, Milosevic et al., 2017).  
 
The resultant hyperactivity in the subthalamic nucleus contributes to the neuron's hyperactivity in the 
Globus pallidus' internal segment (DeLong and Wichmann, 2007). The hyperactivity of the neurons of 
the inner segment of the Globus pallidus leads to an inhibited thalamus, and therefore, reduced signals 
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to the motor cortex (DeLong and Wichmann, 2007). The above results in difficulty initiating and 
executing movement, which accounts for many clinical features used to diagnose PD (DeLong and 
Wichmann, 2007). Other brain areas that play a critical role in the movement are the cerebellum and 
other regions of the cerebral cortex  (Middleton and Strick, 1994, Bostan et al., 2013). The cerebellum 
receives DA signals from the substantia nigra and the ventral tegmental area (VTA), and the dysfunction 
in the BG can lead to impaired signalling in the connected brain areas (Panagopoulos et al., 1991, Ikai 
et al., 1992, Melchitzky and Lewis, 2000). Cerebellar dysregulations and the BG mediate both motor 
and non-motor symptoms of PD (Wu and Hallett, 2013). This is supported by the anatomical 
connections between the BG and the cerebellum (figure 2) (Bostan et al., 2010). There are 
morphological alterations in the cerebellum and the primary motor cortex, which may result from the 
hyperactivity observed in both brain areas in PD patients (Sabatini et al., 2000, Haslinger et al., 2001, 
Borghammer et al., 2010). The hyperactivity within the brain areas is thought to be a compensatory 
mechanism by the defective BG (Sabatini et al., 2000, Wu and Hallett, 2005). The cerebellar-BG-motor 
cortex loop is correlated with motion while the neurons in the BG and cerebellum that circles (figure 2) 
with areas of the prefrontal cortex (PFC) is related to cognitive function (Middleton and Strick, 1994). 
Damage in the BG or the cerebellum will affect the motor function while the resultant dysregulation in 
the non-motor brain areas leads to cognitive deficits and other non-motor symptoms of PD (Middleton 
and Strick, 1994). 
 
L-DOPA treatment has shown to improve clinical symptoms of PD on the Unified Parkinson’s Disease 
Rating Scale motor score (Festini et al., 2015, Mueller et al., 2019). The above improvements were 
accompanied by a connectivity increase between the cerebellum and other brain areas that make up the 
motor system like the brainstem, thalamus, and globus pallidus (Festini et al., 2015, Mueller et al., 
2019). The cerebellum connections to the other brain areas were recognised almost immediately after 
the first L-DOPA dose (Mueller et al., 2019). The improved motor performance was associated with 
increased cerebellar-motor system connectivity, which implies that cerebellar networks can be a crucial 
pharmaceutical target in PD treatments (Mueller et al., 2019). The increased connectivity shows that 
patients on dopaminergic medication recruit the cerebellum during periods of increasing variability 







Figure 1: an illustration of  DA neurons projecting from the substantia nigra pars compacta to the 
striatum, activating the dopamine  D1 receptor on the medium spiny neurons in the direct BG pathway 
(red lines) and dopamine  D2 receptor which inhibits the neurons of the indirect BG pathway (blue 




Figure 2: showing the structural connections between the basal ganglia and the cerebellum. The solid 
lines show the neuronal projections to the striatum from the dentate nucleus, and the dotted lines show 
the axonal projections to the cerebellar cortex from the subthalamic nucleus (Bostan et al., 2010, Wu 
and Hallett, 2013). 
3. Diagnosis of PD  
No one test can definitively diagnose PD; however, it can be diagnosed using a clinical criterion 
(Jankovic, 2008, Mahlknecht et al., 2015). The Movement Disorder Society has criteria for clinical 
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research and PD diagnosis (Postuma et al., 2015). Accurate diagnosis of PD is possible during life, and 
75%-90% of diagnosed cases have been confirmed posthumously (Rizzo et al., 2016). Central to the 
criteria for the diagnosis of PD is cardinal motor symptoms, like bradykinesia, rigidity, resting tremors 
and postural instability (Hughes et al., 1992). Current criteria not only focuses on the motor symptoms 
of PD but also acknowledges non-motor symptoms (Postuma et al., 2015). Non-motor symptoms 
include impaired sense of smell, sleep dysfunction, dysautonomia, and cognitive deficits (Zis et al., 
2015). Motor parkinsonism can be defined as bradykinesia and resting muscle rigidity or resting tremor 
(Postuma et al., 2015). The revised version of the Movement Disorder Society for the confirmation of 
parkinsonism involves four parts, namely, information of their daily non-motor experiences, daily 
motor experiences, an examination of motor skills, and motor complications (Goetz et al., 2008, 
Postuma et al., 2015, Berg et al., 2018). During the diagnosis, the doctor may require other laboratory 
examination from blood to imaging tests, even though these tests cannot confirm PD they can be used 
to rule out other diseases (Kim et al., 2002). A patient must show motor parkinsonism, and those 
symptoms must not be ascribable to any other confounding factors (Postuma and Berg, 2016). 
  
Proving that PD is the causal factor for parkinsonism observed in a patient requires the following 
categories of diagnostic features to be fulfilled, absolute exclusion criteria, at least two supportive 
criteria, and no red flags (Postuma et al., 2015). The absolute exclusion criteria are used to debar PD in 
patients with other mental disorders like behavioural variant frontotemporal dementia (Postuma et al., 
2015). The supportive criteria are met when the patient has a beneficial response to DA replacement 
therapy that is dose-dependent, and a predicted end of the dose wearing off, i.e., a marked on/off 
fluctuation (Postuma et al., 2015). The no red flag criteria are ideal, but the diagnosis of probable PD 
can be made even when the patient presents some red flags provided that for every red flag, there is a 
supportive criterion (Postuma et al., 2015). Examples of red flags include an absence of motor symptom 
progression over five years of observations and rapid gait impairment progression that requires the use 
of a wheelchair (Postuma et al., 2015). The accuracy of diagnosis is dependent on the age of the 
individual, the clinical expertise of the attending clinician, and the duration of the disease (Adler et al., 
2014, Postuma et al., 2015).   
 
In recent years, there has been an increase in the use of imaging techniques used in diagnosing PD 
(Galinowski et al., 2017). Modern technology used in magnetic resonance imaging can show the 
absence of the standard swallow tail sign in the substantia nigra of PD patients and has a 90% accuracy 
of diagnosing PD (Schmidt et al., 2017). The computed tomography scans cannot show a distinct 
difference between patients with PD and the control, but this technology can be used to rule out other 
diseases, making it a useful tool for the diagnosis of PD (Galinowski et al., 2017). Striatal DA activity 
can be determined using the DA reuptake transporter (DAT)–single‐photon emission computed 
tomography (SPECT) (Noyce et al., 2018). This technique quantifies striatal DA activity by using the 
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transcranial sonography and striatal binding ratio, which can be used to identify the hyperechogenicity 
of the substantia nigra of PD patients (Noyce et al., 2018).  
 
A range of cognitive impairments occur in PD, from mild deficits to dementia (Aarsland et al., 2010, 
Litvan et al., 2012, Wang et al., 2015).  There are two criteria for diagnosing cognitive deficits in PD 
as defined by clinical presentation (Yang et al., 2016). Level 1 diagnosis is a brief assessment based on 
the Queen's Square Brain Bank criteria for PD's cognitive deficits (Gibb and Lees, 1991, Hughes et al., 
1992). The mild cognitive decline occurs slowly and can be described by caregivers, patients, or a 
physician can observe it during an examination (Yang et al., 2016). The criteria exclude impairments 
that result from the manifestation of parkinsonism, other possible causes of cognitive decline and 
another factor that occur comorbid with PD that may influence the mental examination results (Emre et 
al., 2007). The mild cognitive deficits eventually progress to dementia in most cases and avoid to errors 
in the diagnosis that may arise more than one neurophysiological test is used (Emre et al., 2007). Mild 
cognitive deficits in PD can be diagnosed with a second criterion which requires two 
neuropsychological tests examining five cognitive domains described by the Movement Disorder 
Society (Yang et al., 2016). The five cognitive domains are neuropsychiatric functions, instrumental 
functions, memory, executive functions and global mental efficiency (Muslimović et al., 2005). 
4. Treatment of PD 
The cure for Parkinson’s disease (PD) is currently non-existent, but there are numerous ways for PD 
patients to maintain a reasonable standard of living. There are medications, physical treatments, and 
surgery that help the patients cope with the disease (Weaver et al., 2009). Surgical intervention is only 
required when the symptoms are not adequately ameliorated with medical therapy (Williams et al., 
2010, Diestro et al., 2018). The subthalamic nucleus can be electrically stimulated to attenuate the 
severity of the advanced PD symptoms (Limousin et al., 1998, Weaver et al., 2009). Examples of such 
cases include PD that presents with essential tremors that are still disabling, even though the patient 
receives adequate doses of medication (Picillo and Fasano, 2016). Patients may need deep brain 
stimulation or lesional surgery in some basal ganglia regions, which can improve severe symptoms of 
PD (Laitinen, 1966, Kumar et al., 1998, Ruonala et al., 2018). 
 
PD patients require rehabilitation to help improve their standard of living reduced by the disease (Hely 
et al., 2008). A rehabilitation program for PD patients includes occupational therapy, speech therapy, 
and physiotherapy (Radder et al., 2017). The above helps improve and maintain mobility, flexibility, 
strength gait speed, speech and overall quality of life (Kluger et al., 2017). The palliative care approach 
provides patients and families affected by PD with some relief from suffering and information that will 




The most effective pharmacotherapy given to help manage PD symptoms is dopamine (DA) 
replacement therapy, which increases DA signalling in the brain (Calne et al., 1969, Qi et al., 2016). 
DA cannot cross the blood-brain barrier because of the charge on the molecule, so a precursor of DA 
called L-3,4-dihydroxyphenylalanine (L-DOPA) is administered orally instead (Kang et al., 2016). 
Enzymes like monoamine oxidase degrade L-DOPA in the periphery, which poses a problem since this 
will reduce the amount of L-DOPA reaching the brain (Brannan et al., 1992, Doudet et al., 1997). 
Therefore, L-DOPA is administered with monoamine oxidase inhibitors and catechol-O-
methyltransferase inhibitors (Brannan et al., 1992, Doudet et al., 1997). L-DOPA can be transported 
across the blood-brain barrier via transcellular passive diffusion (Kageyama et al., 2000). There are 
alternative medications, but none are as effective as L-DOPA. However, L-DOPA causes L-DOPA 
induced dyskinesias (LIDs) in PD patients (Mones et al., 1971).   
5. Pathophysiology of L-DOPA induced dyskinesia 
The Pathophysiology of L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesias (LIDs) is still 
not clearly understood. There are numerous neurotransmitter pathways whose dysregulations are 
implicated in the pathology of LIDs. The molecular pathways implicated include oxidative stress, 
inflammation, mitochondrial dysregulation, imbalanced dopaminergic signalling, impaired 
serotonergic pathway, dysfunction of cholinergic neurotransmission and other molecular pathways 
(Ding et al., 2011, Devos et al., 2013, Michel et al., 2015, de Farias et al., 2016). Oxidative stress due 
to reactive species, nitrogen or oxygen, and reduced activity of catalase enzymes increase the chances 
of dopamine (DA) neuron death in Parkinson’s disease (PD) (de Farias et al., 2016). L-DOPA promotes 
excessive DA release in the striatum, increasing the oxidative stress and the release of pro-inflammatory 
cytokines (de Farias et al., 2016). DA replacement therapy, like L-DOPA, does not necessarily reduce 
the rate of degeneration of DA neurons. The loss of DA neurons in the substantia nigra causes impaired 
DA storage capacity and impaired physiological DA release (Ding et al., 2011, Tronci et al., 2017). It 
is not clear whether L-DOPA promotes DA and serotonin's production and secretion from serotonin 
neurons (Ng et al., 1970, Melamed et al., 2007, Miguelez et al., 2016). Reduction of striatal cholinergic 
tone and the ablation of striatal cholinergic interneurons ameliorates LIDs (Ding et al., 2011, Won et 
al., 2014). Further details need to be elucidated in each pathway to help paint a clear picture of the 
pathology of LIDs. 
5.1. Inflammatory response 
The neuropathology of PD includes non-apoptotic and apoptotic cell deaths, and this injury in the 
nigrostriatal pathway results in activated microglia (Devos et al., 2013). The microglia in the substantia 
nigra and the striatum of PD patients are activated (Kim et al., 2000). Once activated, the microglia 
respond via hypertrophy, proliferation, and release of inflammatory mediators (Devos et al., 2013). 
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Mediators like interleukin-1β, interleukin-6, and tumour necrosis factor-alpha (TNF-α), have been 
shown to play a role in metabolism, ion channel activity and growth factor expression (Mogi et al., 
1994, Kim et al., 2000). TNF-α is a pro-inflammatory cytokine elevated in the striatum, prefrontal 
cortex (PFC), cerebellum and cerebrospinal fluid of PD patients (Mogi et al., 1994, Khadrawy et al., 
2017). This cytokine is thought to work as a transducer of the immune response in brain injuries (Mogi 
et al., 1994). It also has stimulator and cytotoxic properties that prevent infection in the injured area and 
enhances the immune response to brain tissue damage (Mogi et al., 1994). Gliosis may be beneficial at 
times but deleterious at other times as it can lead to increased production of reactive oxygen species 
(ROS) (Kim et al., 2002). ROS generation is counterbalanced by enzymes eliminating ROS compounds 
by detoxifying them (Olufunsho and Ayodele, 2017). One of the features of PD is reduced antioxidant 
capacity, which leads to the oxidation of biomolecules that make up the DA neurons (Campolo et al., 
2016). Unfortunately, the gliosis can lead to the death of DA neurons in a process called glial cell-
mediated neurotoxicity (Liao and Chen, 2001). 
 
The progressive death of DA neurons is a predominant risk factor for LIDs development in PD patients 
(Hong et al., 2014, Bastide et al., 2015). In-vitro studies show that high L-DOPA concentrations can 
initiate the degeneration of cultured DA neurons by inducing both apoptosis and necrosis; how this 
could relate to the brain in the PD condition is unclear (Basma et al., 1995, Ziv et al., 1997). A low L-
DOPA concentration did not show any toxic effects on the cultured dopamine neurons (Mytilineou et 
al., 1993). However, it showed some protective effects against toxicity that could have been mediated 
by peroxide and the upregulation of antioxidant molecules (Han et al., 1996, Warren, 2015). In vivo 
studies and clinical trials have not demonstrated any indication of toxicity, although none of the animal 
models of LIDs is a precise replication of the PD condition (Perry et al., 1984, Lyras et al., 2002). The 
augmented inflammation in PD may lead to heightened effector responses, and one such effector is the 
hypothalamus-pituitary-adrenal (HPA) axis (Ericsson et al., 1994).  
 
5.2. Hypothalamus-pituitary-adrenal axis 
Potent inflammatory cytokines like TNF-α can induce the release glucocorticoids (GCs) by stimulating 
the HPA axis  (Sapolsky and Pulsinelli, 1985, Dunn, 2000). The GCs released from the adrenal glands 
by inflammatory mediators from injured cells or presence of pathogens (Dunn, 2000, Galon et al., 
2002). GCs is thought to have pro-inflammatory and anti-inflammatory properties (Cruz-Topete and 
Cidlowski, 2015). The anti-inflammatory properties are due to the GCs' ability to repress the pro-
inflammatory genes through signal transduction using glucocorticoid receptors (GR) on the surface of 
the immune cells (Cruz-Topete and Cidlowski, 2015). Studies of genome-wide microarrays of human 
mononuclear cells show that GCs can upregulate some innate immune-related genes (Galon et al., 2002, 
Chinenov and Rogatsky, 2007). The GCs bind to GRs and regulate inflammation by altering the 
transcription of target genes and inhibiting the transcriptional factors like NF-kB, AP-1 or interferon 
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regulatory factors (Dunn, 2000, Cruz-Topete and Cidlowski, 2015). In PD patients, the HPA axis is 
hyper-stimulated due to heightened pro-inflammatory cytokines concentration (Herrero et al., 2015). 
However, this imbalance in the HPA axis secretions leads to a high cortisol level and eventual 
dysregulated GRs function in the immune cells (Phillips et al., 2017). In the PD model, microglial GRs 
are activated, which has a significant effect on reducing microglia cell activation and diminishing DA 
degeneration (Pålhagen et al., 2010). GCs play a role in the brain's regulations as it affects the blood-
brain barrier's permeability (BBB) (Kortekaas et al., 2005, Desai et al., 2007). In PD, an impaired BBB 
could lead to cytotoxic molecules' infiltration resulting in increased DA neuron death through chronic 
inflammation (Kortekaas et al., 2005). High secretion of GCs can cause brain tissue injury especially in 
the hippocampus, PFC, and amygdala because of oxidative stress, mitochondrial dysfunction and 
apoptosis (Dinkel et al., 2002, Sato et al., 2010). High oxygen, high iron content, fatty acid peroxidation, 
and low antioxidant capacity in the brain makes it susceptible to oxidative stress (Madrigal et al., 2006). 
The high GCs may increase the risk to develop cognitive or anxiety symptoms, common to brain 
diseases like dementia and depression in which plasticity changes occur (Lucassen et al., 2015). 
 
5.3. Dopamine signalling   
DA plays a crucial role in sleep, learning, attention, pain processing, and working memory (Ayano, 
2016). DA exerts its function via DA receptors which are classified into Gs/Golf-coupled D1-like 
receptors (D1 receptor (D1R) and D5 receptor) and Gi/o-coupled D2-like receptors (D2 receptor (D2R), 
D3 receptor, and D4 receptor) (Ryoo et al., 1998, Yano et al., 2018). DA reuptake transporter (DAT) is 
responsible for terminating DA signalling by pumping the DA molecules back into the cytosol (Howe 
and Dombeck, 2016, Weintraub and Claassen, 2017). In the indirect basal ganglia (BG) pathway, D2Rs 
are inhibitory as they are thought to play a critical role in inhibiting undesired movements (Surmeier et 
al., 2010). The stimulation of D2R modulates neuronal activity and inhibits DA and acetylcholine 
(ACh) release (Tozzi et al., 2011, Threlfell et al., 2012). This complex interaction further affects the 
striato-thalamicortical circuits which affects DA signalling in the cerebellum (Kharkwal et al., 2016, 
Avila-Luna et al., 2018). DA axons that project to the cerebellum are from the substantia nigra and 
ventral tegmental area (Ikai et al., 1992, Flace et al., 2018). Studies have shown the presence of DA 
regulatory machinery and tyrosine hydroxylase, i.e., a rate-limiting enzyme in the synthesis of 
catecholamine in the cerebellum (Diaz et al., 1995, Melchitzky and Lewis, 2000, Flace et al., 2018, 
Qian et al., 2018). DA axons that project to the cerebellum may play a key role in motor control and 
posture regulation (Schweighofer et al., 2004, Dirkx et al., 2017). DA also regulates essential cognitive 
functions through DA receptors expressed in the prefrontal cortex (PFC), striatum and hippocampus 
(Cools et al., 2002, Da Cunha et al., 2002). DA neurotransmission in the PFC plays an essential role in 
mediating executive functions such as the working memory (Arnsten et al., 2015). DA exerts these 
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effects by acting on D1Rs because blockade or stimulation of these receptors in the PFC can impair 
performance on delayed response tasks (Floresco and Magyar, 2006). Little is known about how DA 
mediates the executive functions regulated by the PFC (Meltzer et al., 2019). 
 
Reduced DA signalling, such as in PD, leads to increased D2R expression, i.e., an increased inhibitory 
drive of the indirect pathway and therefore inducing motor impairments (Gerfen et al., 1990, Petzinger 
et al., 2013). Basal ganglia (BG) impairment affects signals that directly or indirectly connect to the BG 
(Floresco and Magyar, 2006, Arnsten et al., 2015). Furthermore, there is an anatomical association of 
cortico-striatal circuitry with the PFC, resulting in executive deficits in PD (Robbins and Cools, 2014, 
Sook et al., 2017). The reduced DA signalling in the BG leads to reduced DA signalling in the PFC, but 
little is known about how cerebellar DA neurotransmission is affected (Parenti et al., 1986, Floresco 
and Magyar, 2006, Petzinger et al., 2013, Arnsten et al., 2015). L-DOPA treatment ameliorates PD 
symptoms by altering cerebellar, limbic, and striatal processing L-DOPA has been shown to improve 
learning and executive cognitive deficits in patients and spatial memory in rodents and monkeys 
(Murphy et al., 1972, Fernández-Ruiz et al., 1999, Cools et al., 2002). However, logical memory deficits 
have been found in treated PD patients compared to untreated patients; moreover, a pre-clinical study 
showed no improvement in learning and memory in rodents (Hietanen and Teräväinen, 1988, Gevaerd 
et al., 2001, Zhao et al., 2016). 
 
Increased striatal D2R signalling in LIDs causes increased motor output, i.e., more severe dyskinesia 
since the direct nigrostriatal pathway is the principal signalling cascade activated in LIDs (Murer and 
Moratalla, 2011, Suárez et al., 2014). Dopaminergic terminals convert L-DOPA into DA which is 
released in the synaptic cleft in a controlled way due to the expression of a regulatory mechanism 
composed of the dopaminergic D2R and the DAT proteins (Bertolino et al., 2009). Thus, D2R and DAT 
can regulate the firing rate of dopaminergic neurons and DA reuptake, respectively, leading to a 
controlled DA release (Bertolino et al., 2009). LIDs associated with long-term L-DOPA use occur due 
to maladaptive striatal plasticity (Bezard et al., 2013, Aristieta et al., 2016). The development of LIDs 
is dependent on the degree of degeneration of dopaminergic neurons, the type of treatment and the 
schedule of administration of the drug (Michel et al., 2015). The first potentiating factor for LIDs is the 
progressive degeneration in the nigrostriatal pathway, which leads to reduced capacity for storing DA 
in the presynaptic vesicles and a reduced physiological DA secretion (Bastide et al., 2015, Tronci et al., 
2017). Additionally, genetically modified mice lacking D1 receptors do not develop LIDs, and a 
combination of D2R agonists and L-DOPA in L-DOPA naïve rodents resulted in zero to mild cases of 
LIDs (Blanchet et al., 1993, Pearce et al., 1998, Darmopil et al., 2009). Furthermore, deletion of D3 
receptors decreases LIDs via targeting D1R-mediated signalling (Darmopil et al., 2009, Solís et al., 
2015). The development of LIDs involves the interaction between DA and the cholinergic system (Conti 
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et al., 2016). DA receptors play a crucial role in the complex interactions between the DA and 
cholinergic systems because the neurons in both systems express D2R (Kharkwal et al., 2016). 
 
5.4. Cholinergic Signalling 
DA and ACh have a feed-forward mechanism since DA can stimulate ( via D5R) or inhibits the release 
(via D2R) of ACh depending on which receptors are stimulated, while ACh stimulates the release of 
DA via nicotinic and muscarinic receptors present on DA neurons (Kharkwal et al., 2016). The striatum 
contains the highest level of ACh and cholinergic markers in the brain, including choline 
acetyltransferase and acetylcholinesterase (AChE) (Kawaguchi et al., 1995, Zhou et al., 2002). ACh is 
an excitatory neurotransmitter in the brain and AChE terminates the neurotransmission by hydrolysing 
ACh to acetate and choline (Maiti et al., 2017). The cholinergic system in the PFC and the hippocampus 
plays a role in learning and memory, and dysfunction in cholinergic signalling may result in cognitive 
deficits (Toyoda, 2018, Gargouri et al., 2019). The loss of nigral DA neuron innervation to the striatum 
in PD leads to a hypercholinergic tone in the BG (Fino et al., 2007, Salin et al., 2009, Tubert et al., 
2016). The increased ACh distorts the function of the network in the brain, which induce structural 
alterations that contribute to PD symptoms (Pisani et al., 2007).  
 
Interestingly, pharmacological reduction of striatal cholinergic tone and ablation of striatal cholinergic 
interneurons (ChIs) have been shown to decrease the severity of LIDs (Ding et al., 2011, Won et al., 
2014). A recent optogenetic study showed that stimulation of cholinergic interneurons modulates LIDs 
severity (Bordia et al., 2016). The changes in striatal cholinergic signalling and DA depletion contribute 
to PD pathology and the appearance of LIDs (Perez et al., 2018). Muscarinic antagonists were among 
the first treatments for PD, although their use is limited by low selectivity and side effects (Duvoisin, 
1967). Striatal DA depletion provokes a reduction in the efficacy of M4 auto-receptors on ChIs, 
resulting in the self-disinhibition of acetylcholine release that contributes to the hypercholinergic tone 
observed with DA depletion (Ding et al., 2006). Dysregulated striatal cholinergic transmission via M1 
and M4 muscarinic receptors has directly been shown to contribute to the motor impairments observed 
with DA depletion in PD (Ztaou et al., 2016). There is an association between LIDs and the aberrant 
striatal output caused by an impaired nigrostriatal pathway and chronic L-DOPA administration (Cenci, 
2014, Bastide et al., 2015). Enhanced cholinergic tone and its facilitation of long-term potentiation, 
along with DA deficiency, are thought to be contributing factors to the development of LIDs (Fino et 
al., 2007, Salin et al., 2009, Cenci and Konradi, 2010, Tubert et al., 2016).  
 
6. Animal models of LIDs 
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Studies in rodent and primate models of L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesias 
(LIDs) have been widely used to understand the pathophysiology related to LIDs and facilitate pre-
clinical testing of novel therapeutics targets (Perez et al., 2018). Animal models represent a pre-clinical 
tool since factors such as disease severity, drug treatment, and comorbidities are easily controlled 
(Nestler and Hyman, 2010). Animal models have been useful in investigating pathogenic pathways and 
therapeutic targets of Parkinson's disease (PD) and LIDs (Francardo and Cenci, 2014). These models 
generally show PD cardinal signs and biochemical and behavioural features (Bové et al., 2005). Most 
animal models of PD show non-motor symptoms such as abnormal olfactory function, gastrointestinal 
problems and sleep disorders (Issy et al., 2015). Animal models of PD are mostly based on dopamine 
(DA) neuron death in the substantia nigra and cellular dysregulation due to toxins like  6-
hydroxydopamine (6-OHDA), 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), rotenone and 
paraquat (Bové et al., 2005, Bezard et al., 2013, Bez et al., 2016). The MPTP-lesioned non-human 
primate model is an excellent symptomatic PD model and was the first model used to reproduce LIDs 
experimentally (Johnston et al., 2010). MPTP recapitulates the motor features of human dyskinesia, that 
is chorea and dystonia and is considered a reliable animal model to define novel therapies (Johnston et 
al., 2010).. The nigrostriatal system's partial lesion is more likely to mimic these earlier stages of PD if 
a lower dose of the toxin was used (Sebastianutto et al., 2016). The unilateral 6-OHDA-lesioned rat 
model can mimic the status of advanced PD and has been widely used for many years to assess drugs' 
symptomatic effects (Picconi et al., 2003, Boix et al., 2015, Michel et al., 2015). The unilateral 6-OHDA 
model presents a side-biased motor impairment, and it allows control of the extent of DA neuron 
degenerations (Beal, 2001). Progression of DA neuron degeneration is most likely the predominant risk 
factor for the appearance of LIDs, but only in subjects with an extensive DA neuron degeneration, 
resulting in more than 80% reduction in striatal DA levels (Hong et al., 2014, Bastide et al., 2015). 
Ulusoy and colleagues (2010) showed that rats whose striatal DA levels had been reduced by 70%, 
without any damage to the striatal dopaminergic innervation (obtained by employing AAV vector 
overexpressing a siRNA for the tyrosine hydroxylase) could develop dyskinesias induced by 
apomorphine. However, they were refractory to dyskinesias generated by L-DOPA (Ulusoy et al., 
2010). Showing that LIDs cannot be induced as long as a sufficient number of DA terminals are present 
to mediate the regulated release of L-DOPA-derived DA (Carta and Björklund, 2018). 
 
7. Basis of the study  
The dopamine (DA) neuron death in Parkinson’s disease (PD) leads to the alterations in the molecular 
markers within the basal ganglia pathways, which affects all the other brain areas that interact directly 
or indirectly with basal ganglia (BG). The brain areas affected lead to more symptoms other than motor 
symptoms, including impaired attention, memory, executive and visuospatial functions. It has been 
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shown that L-3,4-dihydroxyphenylalanine (L-DOPA) ameliorates resting tremors, bradykinesia and 
muscle rigidity in PD patients (Ruonala et al., 2018). L-DOPA can remediate some cognitive deficits. 
It can also induce non-motor fluctuations with cognitive dysfunction, e.g. there is no apparent 
improvement in episodic memory and visuospatial learning and memory (Dubois and Pillon, 1996, 
Robbins and Cools, 2014). Altered DA signalling and cholinergic signalling in the prefrontal cortex 
(PFC) and hippocampus impacts episodic memory acquisition (Morici et al., 2015). Studying the effect 
of L-DOPA on the Hypothalamus-pituitary-adrenal axis and expression of pro-inflammatory markers 
like tumour necrosis factor α will show if L-DOPA exacerbates glial cell linked neurotoxicity in the 
BG, PFC, and the cerebellum. If this is so, the exaggerated neurotoxicity in PD patients may play a 
significant role in the development of LIDs and cognitive decline (Pisanu et al., 2018, Boi et al., 2019). 
L-DOPA medication results in LIDs and these behavioural fluctuations may not only be limited to 
motor fluctuations. More work focusing on the social aspects, cognitive impairment, and mood 
dysfunction in PD need to be done to understand other effects of LIDs. The present study aimed to 
investigate the gradual effect of L-DOPA treatment on the inflammation, HPA axis, cholinergic 
pathway and dopaminergic pathway using molecular markers for each pathway in the cerebellum, PFC 
and striatum of rats that were unilaterally lesioned with 6-OHDA in the medial forebrain bundle. 
Objectives 
• To assess basal motor function and dyskinesias.  
• To assess cognitive deficit. 
• To determine the level of corticosterone (plasma)   
• To assess the level of TNF-α (striatum and PFC). 
• To assess the level of DA (PFC and striatum) and the expression of D1 (PFC) and D2 
(striatum). 
• To assess the level of AChE in the PFC, hippocampus, and striatum. 
 
8. General methodology  
The present study received ethical approval (AREC/077/018M) from the University of KwaZulu-
Natal's Animal ethics committee. Seventy-two adult male Sprague-Dawley (SD) rats with weights 
ranging from 220-250 g were obtained from the Biomedical Resource Unit at the University of 
KwaZulu-Natal and were used in the present study. After the rats were acclimatised, they were trained 
for the elevated beam walking test (EBWT) for two days and assessed on the third day. A day later the 
SD rats were separated into two groups where one group was intracranially injected with saline (4 µL) 
and the second group was lesioned with 6-hydroxydopamine (6-OHDA) (8 μg/4 μl dissolved in 0.2% 
ascorbic acid) in the right side of the medial forebrain bundle. The SD rats included in the first phase 
of the present study went through handling or received a subcutaneous injection of saline or L-3,4-
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dihydroxyphenylalanine (L-DOPA) (50 mg/kg) and benserazide (10 mg/kg) for 14 days. During the 
first day of treatment, 1 hour after handling and administering the L-DOPA or saline, the SD rats' 
balance and coordination were assessed using the EBWT (figure 3). The SD rats' object recognition 
memory, visuospatial learning and spatial memory were assessed using the novel object recognition test 
(NORT) and the Morris water maze test (MWMT) (figure 3).  
  
The second phase of the present study includes SD rats that developed dyskinesias after subcutaneous 
injections of L-DOPA and benserazide for the treatment duration of 28 days. The dyskinesias 
experienced by the group were recorded between 9 am to 10 am and scored using the abnormal 
involuntary movements (AIMs) score. Once the AIMs have receded, the animals are given an hour to 
rest. Once the SD rats were rested, the SD rats' balance and coordination were assessed using the EBWT. 
The SD rats' objection recognition memory, visuospatial learning and spatial memory were assessed 
using the NORT and the MWMT (figure 3).  
  
SD rats were sacrificed, and the blood, cerebella, striata, hippocampus, and the prefrontal cortex (PFC) 
collected for neurochemical analysis. The collected tissues were analysed to determine striatal 
dopamine (DA) concentration, cerebellar DA concentration, striatal tumour necrosis factor α (TNF-α) 
concentration, striatal acetylcholinesterase (AChE) concentration, cerebellar TNF-α concentration, PFC 
DA concentration, PFC AChE, PFC TNF-α concentration, hippocampal AChE concentration, and 
plasma corticosterone concentration using Enzyme-linked Immunosorbent assay (ELISA) kit. 
Furthermore, D1 and D2 receptor expressions were determined using reverse transcription-polymerase 
chain reaction to analyse the PFC and striatum, respectively. The study design and timeline are 






























Figure 3: illustration of the study design and timeline for the induction of parkinsonism and treatment 
with L-DOPA.  
Male Sprague Dawley rats from BRU (n=72).  Day 0 
Rats were given 7 days of acclimatization and were then randomly separated. Day 0-7   
Behavioural training and test: Elevated beam walking test (EBWT). Day 8-10 
Stereotaxic surgery/ Lesioning. Day 11 
Positive control and Test (n=48)→6-OHDA Control (n=24) ➔ Saline  
 
7 days for the lesion to stabilise. Day 12-19 
First day of treatment (Day 20). Behavioural test: EBWT → Day 20 (Pre-LID) and Day 40 (LID) 
Pre-LID Phase  LID Phase 




















NORT and MWMT. Day 28-33 NORT, MWMT and AIMS score. Day 41-47 
 
ELISA Assay → TNF-α, DA, AChE, and corticosterone    
RT-PCR → D1 and D2 receptor expression  
(n=3/group) 
SD Rats were sacrificed,→ trunk blood, cerebella, 
striata, PFC, and hippocampus were collected and Snap 
frozen in liquid nitrogen.   
The collected samples were stored in a bio-freezer at -
80˚C for neurochemical analysis. 
Day 34 
 
SD Rats were sacrificed,→ trunk blood, cerebella, 
striata, PFC, and hippocampus were collected and Snap 
frozen in liquid nitrogen.  
The collected samples were stored in a bio-freezer at -
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Dopamine (DA) signalling deficiency within the basal ganglia has been shown to result in motor 
symptoms that are features of Parkinson's disease (PD). The golden standard for treating PD symptoms 
is the DA replacement therapy called L-3,4-dihydroxyphenylalanine (L-DOPA), which increases DA 
signalling in the basal ganglia. However, prolonged use of L-DOPA leads to abnormal involuntary 
movements called L-DOPA induced dyskinesias (LIDs). L-DOPA remains the most effective PD 
treatment, hence gathering information to ascertain dysregulations that lead to the development of LIDs 
is essential. Studies have used the 6-OHDA rat model of PD to imitate dyskinesias' development by 
treating 6-OHDA lesioned rodents with L-DOPA. In addition to the basal ganglia, the cerebellum is 
also associated with motor function. The present study investigates the alteration of striatal AChE and 
cerebellar DA as abnormal involuntary movements develop in a rat model of LIDs. 
 
The present manuscript was prepared according to the author guidelines for the Journal brain research. 
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Forty to sixty per cent of Parkinson's disease (PD) patients on chronic L-3,4-dihydroxyphenylalanine 
(L-DOPA) treatment develop abnormal involuntary movements (AIMs) called L-DOPA induced 
dyskinesias (LIDs). The present study investigates the alteration in striatal acetylcholinesterase (AChE) 
and cerebellar dopamine (DA) concentration as abnormal involuntary movements develop in a rat 
model of LIDs. 6-hydroxydopamine (6-OHDA) was used to unilaterally lesion the medial forebrain 
bundle of Sprague-Dawley rats to induce parkinsonism which was treated with L-DOPA. The motor 
skills were assessed using the elevated beam walking test and the abnormal involuntary movement 
score. Tumour necrosis factor-alpha (TNF-α), AChE, and DA concentrations, and the expression of 
dopaminergic D2 receptor (D2R) were measured. L-DOPA treatment alleviated 6-OHDA-induced 
hypokinesia and motor incoordination, while prolonged L-DOPA treatment led to AIMs. L-DOPA 
treatment increased striatal TNF-α and DA concentration as well as D2R expression but reduced striatal 
AChE concentration. Reduced AChE concentration impairs the regulation of ACh signalling indirectly 
affecting DA signalling. The progressive increase in striatal D2R and DA between 14 and 28 days of 
treatment may play a vital role in the appearance of AIMs. Cerebellar TNF-α and DA concentrations 
were elevated following 14 days of L-DOPA treatment, but both markers were decreased following 28 
days of treatment. Increased cerebellar DA concentration in the L-DOPA treated group resulted in 
improved motor skills. However, reduced cerebellar DA occurred with AIMs and hypokinesia, 
demonstrating the cerebellum's involvement in PD and LIDs pathology. 
 








Parkinson's disease (PD) is a disease whose phenotype includes motor symptoms like bradykinesia and 
akinesia which are a result of impaired basal ganglia (BG) signalling that prevails in the disease state 
(Boecker et al., 1999, Postuma and Berg, 2016). The BG is a subcortical nuclei group that plays a role 
in initiating desired and inhibition of undesired movements (Ungerstedt, 1968, Middleton and Strick, 
1994). PD is characterised by dopamine (DA) neurons' death in the pars compacta of the substantia 
nigra (Issy et al., 2015). The death of DA neurons results in diminished DA neurotransmission in the 
striatum, which results in motor symptoms such as hypokinesia, that are characteristic of PD (Zhai et 
al., 2018).  
 
Effective medication used to treat motor symptoms of PD is the DA replacement therapy that includes 
a combination of L-3,4-dihydroxyphenylalanine (L-DOPA) and inhibitors of monoamine oxidase and 
catechol-O-methyltransferase (Cotzias et al., 1969, Männistö et al., 1990, Kang et al., 2016). The 
inhibitors are administered to lessen the peripheral degradation of L-DOPA, therefore enhancing the 
concentration of L-DOPA that reaches the central nervous system, where it can be converted to DA-
thus, increasing DA neurotransmission in PD patients' striatum (Törnwall and Männistö, 1993, Stacy 
and Galbreath, 2008, Ruonala et al., 2018). One of the significant side-effects of long-term use of L-
DOPA is the development of abnormal involuntary movements called L-DOPA induced dyskinesias 
(LIDs) (Cotzias et al., 1969, Ko et al., 2014, Conti et al., 2016). Forty per cent of PD patients develop 
LIDs after using L-DOPA for six years, this percentage increases to sixty per cent after ten years of 
treatment (Ahlskog and Muenter, 2001, Tran et al., 2018). Factors that predispose PD patients to 
develop LIDs include, age of PD onset, body weight, the dose of L-DOPA prescribed and others 
(Daneault et al., 2013).  
 
The pathophysiology of LIDs is still under investigation. However, some of the findings implicated 
impaired striatal DA signalling, increased conversion of L-DOPA to dopamine by striatal serotonin 
neurons, impaired cholinergic fibre signalling, and neuroinflammation (Murer et al., 1998, Shen et al., 
2015, Ndlovu et al., 2016, Smith et al., 2016). Neuroinflammation is central to the pathology of PD as 
it is thought to not only be a result of the disease itself but also to propagate the death of DA neurons 
via pro-inflammatory cytokines like tumour necrosis factor-alpha (TNF-α) (Mogi et al., 1994, Jin et al., 
2008, Tufekci et al., 2012). The release of pro-inflammatory cytokines like TNF-α is beneficial in the 
early stages of the disease as it enhances the immune response to the tissue damage occurring in PD 
(Boka et al., 1994, Tufekci et al., 2012). However, as the disease progresses, this augmented 
inflammatory response leads to increased synthesis of reactive oxygen species that eventually cause the 




DA neurons can convert L-DOPA into dopamine which is released in the synaptic cleft in a controlled 
manner due to the expression of a delicate regulatory mechanism composed of the dopaminergic D2 
receptor (D2R) and the DA active transporter proteins (Bertolino et al., 2009, Kintz et al., 2017). The 
decreased DA signalling in PD has been shown to lead to increased D2R sensitivity as a compensatory 
mechanism (Petzinger et al., 2013, Kintz et al., 2017). The increased endogenous DA production due 
to L-DOPA therapy and increased D2R sensitivity in the basal ganglia causes increased motor 
complications, i.e., LIDs (Parenti et al., 1986, Surmeier et al., 2010, Murer and Moratalla, 2011, 
Petzinger et al., 2013).  
 
Striatal cholinergic interneurons express D2R, which, when stimulated, inhibits ACh secretion and 
reduced DA signalling, such as in PD, leading to increased ACh signalling (Soreq, 2015, Souza et al., 
2015). The changes in striatal cholinergic signalling and DA depletion contribute to PD pathology and 
the appearance of LIDs (Perez et al., 2018). The ablation of cholinergic neurons, i.e., decreased striatal 
ACh concentration, has been shown to decrease the severity of LIDs (Ding et al., 2011, Won et al., 
2014). ACh signalling is regulated by a group of enzymes called Acetylcholinesterase (AChE) that 
break down ACh to acetate and choline, a critical process that regulates ACh signalling (Zugno et al., 
2015). Studying the role that AChE plays in the pathology of PD and LIDs is essential for the 
development of more pharmaceutical interventions that can reduce the severity of LIDs. 
 
The study of molecular changes in PD that lead to the development of LIDs has been done in humans 
and animal models. One such animal model that can mimic the death of DA neurons in the medial 
forebrain bundle and the resulting parkinsonism is the 6-hydroxydopamine (6-OHDA) rodent model of  
PD  (Paxinos and Watson, 1986). The neurotoxin is injected into the medial forebrain bundle, affecting 
the DA neurons in the substantia nigra (Ngema and Mabandla, 2017). The reduced DA signalling affects 
the basal ganglia, especially the striatum leading to impaired motor skills (Zarow et al., 2003). The 
ventral tegmental area and substantia nigra supply DA to the cerebellum but not much is known about 
cerebellar DA content in PD patients (Ikai et al., 1992, Flace et al., 2018). The administration of L-
DOPA can affect DA signalling in the cerebellum. The present study investigates the alteration of 




2.1 The Elevated Beam walking test 
Motor coordination and balance were assessed before (pre-lesion) and seven days after stereotaxic 
surgery (post-lesion) in the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), Sal (28), 6-OHDA 
(28), and L-DOPA (28), figure 1. The two-way analysis of variance followed by Sidak's multiple 
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comparisons test was used to analyse the data in figure 1. The 6-OHDA lesion significantly increased 
the time taken to cross the beam (pre-lesion vs post-lesion; 6-OHDA (14); 6-OHDA (28); F 5, 60 = 
28,53, p<0.0001, figure 1a) and the number of foot slips observed when crossing the beam (pre-lesion 
vs post-lesion; 6-OHDA (14); 6-OHDA (28); F5, 60= 16.04, p<0.0001, figure 1b). Treatment with L-
DOPA significantly reduced the time to cross the beam (6-OHDA (14) vs L-DOPA (14); 6-OHDA (28) 
vs L-DOPA (28); F 5, 60 = 22,64, p<0.0001, figure 1a) and significantly reduced the number of foot 
slips (6-OHDA (14) vs L-DOPA(14); F5, 60= 14,4, p<0.0001, figure 1b) and L-DOPA (28) (6-OHDA 
(28) vs L-DOPA (28); F5, 60 = 14,4, p=0,0001, figure 1b).  AIMs development in the L-DOPA (28) 
group increased the time the SD rats took to reach the home cage (pre-lesion vs post-lesion, L-DOPA 
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Figure 1: Graph showing (a) the time it took the SD rats to reach the home cage and (b) the number of 
foot slips observed as SD rats crossed the beam in the Elevated beam walking test (n=11per group). 
 
2.2 The abnormal involuntary movement score 
Abnormal involuntary movements were rated in L-DOPA (28), figure 2. The two-way analysis of 
variance followed by Sidak's multiple comparisons test was used to analyse the data in figure 
2. There was no significant difference in the severity of AIMs in the L-DOPA (28) group in the eight 


















































































Figure 2: Graph showing the average severity of the abnormal involuntary movements in the L-DOPA 
(28) group for eight days of treatment (n=10). 
 
2.3 The striatal tumour necrosis factor-alpha concentration 
Striatal TNF-α concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA 
(14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 3. One-way analysis of variance plus 
Tukey's multiple comparisons test was used to examine the data in figure 3. TNF-α 
concentration was significantly increased in 6-OHDA-lesioned rats at day 14 of saline injections (Sal 
(14) vs 6-OHDA (14); F5, 12 = 27.2, p= 0,0078, figure 3). This effect was also observed at day 28 of 
saline injections (Sal (28) vs 6-OHDA (28); F5, 12 = 27.2, p< 0,0088 figure 3). TNF-α concentration 
was significantly heightened after 14 days (Sal (14) vs L-DOPA (14); F5, 12 = 27.2, p= 0,0154, figure 
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Figure 3: Graph showing striatal TNF-α concentration in the following groups: Sal (14), 6-OHDA 
(14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
2.4 The concentration of cerebellar Tumour necrosis factor-alpha (TNF-α) 
Cerebellar TNF-α concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-
DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 4. One-way analysis of variance 
plus Tukey's multiple comparisons test was used to examine the data in figure 4. TNF-α 
concentration was significantly increased in 6-OHDA-lesioned rats at day 14 (Sal (14) vs 6-OHDA 
(14); F5, 12 = 29.47, p= 0.0067, figure 5) and day 28 (Sal (28) vs 6-OHDA (28); F5, 12 = 29.47, p< 
0.0001, figure 5). Treatment with L-DOPA for 14 days significantly increased TNF-α concentration 
(Sal (14) vs L-DOPA (14); F5, 12 = 29.47, p= 0.0024, figure 5), while 28 days of treatment 
significantly decreased it (6-OHDA (28) vs L-DOPA (28); F5, 12 = 29.47, p< 0,0001, figure 4). TNF-
α concentration significantly increased with time in the 6-OHDA lesioned groups only (6-OHDA (14) 































































































Figure 4: Graph showing cerebellar TNF-α concentration in the following groups: Sal (14), 6-OHDA 
(14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
2.5 The concentration of dopamine in the striatum 
Striatal DA concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA 
(14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 5. One-way analysis of variance plus 
Tukey's multiple comparisons test was used to examine the data in figure 3.  DA concentration 
was significantly decreased in 6-OHDA-lesioned rats 14 days (Sal (14) vs 6-OHDA (14); F2, 10 = 
3.288, p<0,0001, figure 5) and (Sal (14) vs L-DOPA (14); F2, 10 = 3.288, p= 0.0003, figure 5) and 28 
days (Sal (28) vs 6-OHDA (28); F2, 10 = 3.288, p<0.0001, figure 5) and (Sal (28) vs L-DOPA (28); 
F2, 10 = 3.288, p= 0.0019, figure 5) post treatment. However, there was a treatment effect in the 6-
OHDA lesioned groups (6-OHDA (14) vs L-DOPA (14); F2, 10 = 3.288, p= 0.0147, figure 5) and (6-
OHDA (28) vs L-DOPA (28); F2, 10 = 3.288, p= 0.0011, figure 5). Furthermore, there was a time 
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Figure 5: Graph showing striatal DA concentration in the following groups: Sal (14), 6-OHDA (14), L-
DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
2.6 The concentration of DA in the cerebellum  
Cerebellar DA concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA 
(14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 6. One-way analysis of variance plus 
Tukey's multiple comparisons test was used to examine the data in figure 6. DA concentration 
was significantly increased in 6-OHDA-lesioned rats 14 days of treatment (Sal (14) vs 6-OHDA (14); 
F5, 12 = 34.1, p= 0,0035, figure 6) and (Sal (14) vs L-DOPA (14); F5, 12 = 34.1, p= 0,0006, figure 
6). Cerebellar DA was significantly elevated in the 6-OHDA lesioned rats 28 days post-lesion (Sal 
(28) vs 6-OHDA (28); F5, 12 = 34.1, p= 0,0002, figure 6). However, the 6-OHDA lesioned rats that 
were treated with L-DOPA for 28 days had a significantly lower cerebellar DA concentration (6-
OHDA vs L-DOPA (28); F5, 12 = 34.1, p< 0,0001, figure 6). The rats treated with L-DOPA for 28 
days had a significantly decreased cerebellar DA concentration as compared to the group treated for 
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Figure 6: Graph showing cerebellar DA concentration in the following groups: Sal (14), 6-OHDA (14), 
L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
2.7 The expression of Dopamine 2 receptor in the striatum  
Striatal D2R expression was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), 
Sal (28), 6-OHDA (28), and L-DOPA (28), figure 7. One-way analysis of variance plus Tukey's 
multiple comparisons test was used to examine the data in figure 7. There was a significant upregulation 
of D2R gene expression as time progressed in the 6-OHDA lesioned groups (6-OHDA (14) vs 6-OHDA 
(28), F5, 12 = 25.86, p= 0,0004, figure 7) and (L-DOPA (14) vs L-DOPA (28); F5, 12 = 
25.86, p= 0,0011, figure 7). There was a lesion effect 35 days post lesion (Sal (28) vs 6-OHDA (28); 
































































































Figure 7: Graph showing the change in D2R expression relative to GAPDH expression in the striata of 
the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA 
(28) (n=3 per group).  
 
2.8 The concentration of acetylcholinesterase in the striatum  
Striatal AChE concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA 
(14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 8. One-way analysis of variance plus Tukey's 
multiple comparisons test was used to examine the data in figure 8. AChE concentration was 
significantly increased in 6-OHDA lesioned rats (Sal (14) vs 6-OHDA (14); F5, 12 =114.1, p < 
0,0001, figure 8) and (Sal (28) vs 6-OHDA (28); F5, 12 = 114.1, p < 0,0001, figure 8). AChE 
concentration was significantly reduced in 6-OHDA lesioned rats that were treated with L-DOPA(6-
OHDA (14) vs L-DOPA (14); F5, 12 = 114.1, p< 0,0001, figure 8) and (6-OHDA (28) vs L-DOPA 
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Figure 8: Graph showing striatal AChE concentration in the following groups: Sal (14), 6-OHDA (14), 
L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
3. Discussion 
L-DOPA is still the most effective pharmacological intervention for motor complications related to 
Parkinson’s disease (PD) (Kang et al., 2016). However, chronic treatment of PD with L-3,4-
dihydroxyphenylalanine (L-DOPA) has been known to progressively lead to abnormal involuntary 
movements (AIMs) (Bezard et al., 2013, Aristieta et al., 2016). The neurotoxin 6-hydroxydopamine (6-
OHDA) causes the degeneration of dopamine (DA) neurons in the nigrostriatal pathway, which leads 
to motor impairment in a rat model of PD (Schober, 2004). The rodent 6-OHDA model has been 
modified by treating the rodents with a combination of L-DOPA and benserazide for 28 days post-6-
OHDA surgery to model the development of L-DOPA-induced dyskinesias (LIDs) (Picconi et al., 2003, 
Lundblad et al., 2005, Ndlovu et al., 2016). Previous studies have shown that the administration of L-
DOPA led to the development of AIMs after 21 days of treatment (Ndlovu et al., 2016). The present 
study investigated motor complications related to prolonged exposure to L-DOPA in a unilaterally 
lesioned 6-OHDA rat model of PD. The present study further explored cerebellar (DA and tumour 
necrosis factor-alpha (TNF-α)) and striatal (TNF-α, Acetylcholinesterase (AChE), DA and 
dopaminergic D2 receptor (D2R)) molecular marker alterations in the progression of L-DOPA 




In the present study, the elevated beam walking test (EBWT) was used to assess two motor skills, viz. 
hypokinesia and fine coordination (Carter et al., 2001, Luong et al., 2011). The 6-OHDA lesion caused 
hypokinesia, incoordination and motor imbalance which was observed on the 8th and 27th-day post-
surgery. These results agree with reports showing rats intracranially injected with 6-OHDA in the 
medial forebrain bundle showed motor impairments (Pierucci et al., 2009, Chen et al., 2018). The motor 
impairments were ameliorated by L-DOPA as assessed on the first day of treatment and the 20th day of 
treatment using the EBWT. These findings agree with literature that showed that the motor impairment 
that resulted from a unilateral 6-OHDA lesion is ameliorated by L-DOPA treatment  (Strome et al., 
2007, Ordoñez-Librado et al., 2010). However, prolonged exposure to L-DOPA resulted in AIMs with 
a consistent score for the eight days of observation (from the 21st day to the 28th day of treatment). These 
findings align with Ndlovu et al., (2016), who found that rats treated with L-DOPA after a unilateral 6-
OHDA lesion in the medial forebrain bundle resulted in AIMs 21 days post-L-DOPA administration. 
The development of AIMs has been attributed to impaired DA signalling in the striatum (Ahlskog and 
Muenter, 2001).  
 
PD is associated with chronic inflammation, and the injection of 6-OHDA in the medial forebrain 
bundle has shown to result in an inflammatory response (Farbood et al., 2015). One of the main effectors 
of inflammation is the pro-inflammatory cytokine TNF-α, and the increased expression of this 
biomarker in PD shows that it may be a mediator of neural damage via oxidative stress (Boka et al., 
1994, Nagatsu et al., 2000). Under normal conditions, TNF-α is not toxic to DA cells but persistently 
high expression of TNF-α can lead to notable death of DA neurons (Boka et al., 1994, Leal et al., 2013). 
The present study showed that a 6-OHDA lesion increased striatal TNF-α concentration, suggesting 
that the neurotoxin causes hyper-inflammation in the striatum, a state that remained in the striatum 
throughout treatment with L-DOPA (Mogi et al., 1994, Mogi et al., 1999). The 6-OHDA lesion 
increased cerebellar TNF-α concentration with a progressive increase observed from week two to week 
four in the untreated 6-OHDA groups. Increased cerebellar and striatal TNF-α concentration show a 
heightened inflammatory state, leading to the death of DA neurons via glial cell-mediated neurotoxicity  
(Hwang et al., 2008, Chung et al., 2016). These findings show that PD has pathophysiological features 
that allow the death of DA neurons to occur in other brain areas besides the basal ganglia (BG) and 
prevails in the disease state (Khadrawy et al., 2017). 
 
DA signalling is tightly regulated by DA receptors and DA reuptake transporter (Howe and Dombeck, 
2016). DA neurons convert endogenous L-DOPA to DA which is released into the synaptic cleft, and 
the DA transporters facilitate reuptake of DA into the presynaptic neuron (Männistö et al., 1990, Howe 
and Dombeck, 2016). In PD and animal models of the disease, there is a death of DA neurons resulting 
in reduced DA signalling in the striatum (Lai et al., 2019). In our study, the intracranial injection of 6-
OHDA into the medial forebrain bundle led to DA concentration reduction in the striatum. These results 
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align with Lai et al., 2019, who showed that the intracranial injection of 6-OHDA in the medial 
forebrain bundle reduced striatal DA content. The administration of L-DOPA increased DA signalling 
in the striatum and along with the hypersecretion of DA in the cerebellum ameliorated the motor 
impairment that prevails due to the 6-OHDA lesion (Bertolino et al., 2009). However, comparing the 
striatal DA concentration after 14 days of L-DOPA treatment and after 28 days of L-DOPA 
administration showed a progressive increase in striatal DA concentration. The severely depressed 
striatal DA signalling due to the loss of DA neurons causes the recruitment of striatal serotonin neurons 
that uptake exogenous L-DOPA and produce DA (Ng et al., 1970, Maeda et al., 2005, Bastide et al., 
2015). The issue with the above  mechanism is that it does not have the same regulatory mechanism for 
DA release as the DA neurons (Tanaka et al., 1999). DA released from serotonergic neurons will act in 
coordination with orally administered L-DOPA to cause pulsatile stimulation of DA receptors, which 
cause changes in downstream signalling pathways in striatal neurons and contributes to the development 
of LIDs (Tanaka et al., 1999, Björklund et al., 2007, Carta and Björklund, 2018). The unregulated 
release of striatal DA by serotonin neurons leads to uncontrolled movements, i.e., AIMs observed in 
the present study. 
 
Cerebellar DA sources are axonal projections from the ventral tegmental area and the substantia nigra 
(Ikai et al., 1992, Flace et al., 2018). There was increased cerebellar DA concentration in groups 
lesioned with 6-OHDA except in the group treated with L-DOPA for 28 days. Humans and animal 
studies showed hyperactivity in the cerebellum and motor cortex in response to the reduced signalling 
in the substantia nigra. Furthermore, there is increased connectivity between the cerebellum and other 
brain areas in PD patients off L-DOPA treatment (Festini et al., 2015). The increased activity and 
connectivity is thought to compensate for the depressed neurotransmission in the BG in PD. In the 
present study, the hyperactivity observed in the cerebellum is increased DA signalling in rodents 
lesioned with 6-OHDA. The above may be due to increased connectivity to the VTA in response to 
depressed DA signalling in the BG. PD patients on L-DOPA treatment had reduced connectivity 
between the cerebellum and other brain areas (Festini et al., 2015). Initially, the treatment with L-DOPA 
for 14 days showed a high cerebellar DA concentration, but there was a significant reduction of 
cerebellar DA concentration after 28 days of treatment.   
 
The second factor that plays a role in the regulation of DA transmission is DA receptors. DA receptors 
help facilitate the action of DA and are often the target site for DA therapy drugs  (Ryoo et al., 1998). 
In the present study, the unilateral lesion using 6-OHDA and the resultant DA depression resulted in 
heightened D2R expression in the ipsilateral striatum. The upregulated D2R expression becomes more 
prominent as time progressed from 14 days to 28 days of treatment. These findings align with literature 
which shows that in PD the reduced DA signalling causes an increased D2R expression in the striatum 
as a compensatory mechanism, i.e., rendering the post-synaptic neuron more sensitive to DA (Gerfen 
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et al., 1990, Nikolaus et al., 2003, Smith et al., 2016). Initially, the treatment with L-DOPA for 14 days 
showed a tendency to reduce the D2R expression, but after 28 days of treatment, the expression of D2R 
increased significantly. These findings align with Narang and Wamsley (1995) who found a significant 
increase in D2R expression from the second week to the sixteenth-week post-lesion. This increased 
expression and increased DA production from exogenous L-DOPA administration may increase motor 
output, i.e., AIMs (Murer and Moratalla, 2011).  
 
D2Rs are expressed on acetylcholine (ACh) neurons, and once stimulated, they inhibit the activation 
and release of ACh (Kharkwal et al., 2016). The reduced activity of the dopaminergic system in the 
striatum has been shown to occur in parallel with the cholinergic system's hyperactivity (Dagaev et al., 
2004, Fino et al., 2007, Salin et al., 2009, Tubert et al., 2016). In normal physiological conditions, ACh 
signalling is tightly regulated by cholinergic receptors and AChE  (Kawaguchi et al., 1995, Zhou et al., 
2002). AChE is an enzyme that hydrolyse extracellular ACh and is sometimes used as a cholinergic 
biomarker (Zaretsky et al., 2016). In the present study, the 6-OHDA lesion alone showed increased 
striatal AChE concentration. The reduced DA signalling in the 6-OHDA lesioned groups has been 
shown to lead to an increased ACh as a compensatory mechanism since ACh stimulates DA secretion 
from DA neurons (Ding et al., 2011). The heightened ACh signalling increases AChE concentration, 
allowing for pulsatile release of ACh and diminishing the chances of receptor desensitization on the 
DA neuron (Zhou et al., 2001). Increased DA signalling, such as in the groups treated with L-DOPA, 
reduces ACh's secretion and eventually decreased the concentration of the enzyme AChE. ACh and DA 
have a feedforward mechanism since DA neurons also have nicotinic and muscarinic receptors that, 
when activated lead to the DA release (Kharkwal et al., 2016). The reduced striatal AChE in groups 
treated with L-DOPA increases ACh signalling which may play a vital role in the development of LIDs 
since the pharmaceutical reduction of cholinergic signalling has been shown to reduce the severity of 
LIDs (Ding et al., 2011, Won et al., 2014). 
 
4. Conclusion 
The present study showed that L-DOPA attenuates the hypokinesia and impaired motor coordination 
caused by the injection of 6-OHDA into the medial forebrain bundle. The hypokinesia returned after 
the development of AIMs because of increased DA signalling and reduced AChE concentration in the 
striatum. The present study showed that the hyperactivity and increased connectivity previously 
reported in PD patients' cerebellum off L-DOPA treatment would translate to increased cerebellar DA 
concentration and hyper-inflammation (Festini et al., 2015, Mirdamadi, 2016). The prolonged treatment 
with L-DOPA reduced cerebellar DA concentration and hyperinflammation. This reduction may be 
because of decreased connectivity between the cerebellum and other brain areas (Festini et al., 2015). 
There was a progressive increase in DA signalling in the striatum during prolonged L-DOPA treatment 
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which causes a progressive decline in DA signalling in the cerebellum. Furthermore, the present study 
showed that prolonged treatment reduces hyper-inflammation in the cerebellum, which reduces the 
chance of cerebellar neuronal degeneration. These findings suggest that DA plays a crucial role in the 
pathology of PD and LIDs. The findings may be beneficial to reduce the disease's progression and 
reduce the chances of developing dyskinesias. This increases the longevity and quality of life for PD 
patients. Future studies may focus on the progressive alteration of the apoptotic marker in the 
cerebellum, thalamus, and motor cortex to illuminate the heightened inflammatory response's effect on 
the neurons in the cerebellum. 
 
5. Materials and methods 
5.1 Animal Care and Housing  
The University of KwaZulu-Natal's Animal Research Ethics Committee (AREC/077/018M) granted 
the present study ethical approval. Upon ethical approval, seventy-two adult male Sprague-Dawley 
rats with weights ranging from 220-250 g were obtained from the Biomedical Resource Unit of the 
University of KwaZulu-Natal. The rats were housed in clear cages and given standard rat feed and 
water freely. The holding area where the rats were kept for the study's duration was under standard 
laboratory conditions and a 12-hour light/dark cycle with lights automatically switching on at 06:00. 
The rats were given an acclimatisation period of 7 days before any behavioural tests. 
 
5.2 Elevated Beam walking test 
In the present study, the elevated beam walking test was used to assess two motor skills, i.e., fine 
coordination and balance (Carter et al., 2001, Luong et al., 2011). The elevated beam walking test 
(EBWT) was performed twice, before the 6-OHDA lesion and after the lesion has stabilised (figure 
9). This task includes a training  phase that happens over two days, followed by a 1-day assessment 
(figure 9). The training phase included the rats being trained to cross an 80 cm long, 4 cm wide beam 
on the first day, followed by a 60 cm long, 3 cm wide wooden beam on the second day to reach the 
goal box. On the day of the assessment, the rats crossed a 60 cm long, 2 cm wide wooden beam to 
reach the goal box. During the training and assessment, the wooden beam was 30 cm above a soft 
surface on a wooden frame. The rats that fell off were returned to the starting position, and the timer 
restarted. The parameters measured during the assessment was the time taken for the rat to cross the 
narrow beam and the number of foot slips that the animals displayed as they crossed the beam. 
 
5.3 Stereotaxic surgery  
The rats were placed under chemical anaesthesia prior to surgery. The chemicals used were a 
combination of ketamine and xylazine (125 mg/kg and 10 mg/kg, respectively) which was administered 
via intraperitoneal injection (Veilleux-Lemieux et al., 2013). The ketamine keeps the rats in a state of 
unconsciousness, and xylazine helps increase the heart rate to prevent hypotension during surgery 
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(Bennett and Bullimore, 1973, Veilleux-Lemieux et al., 2013). Once the rat was unconscious, it was 
placed in the stereotaxic frame (David Kopf Instruments, Tujunga, USA). The scalp was marked at the 
following coordinates from the lambda 4.7 mm anterior and -1.6 mm from the midline (Paxinos and 
Watson, 1986). A small hole was drilled at the marked area and a Hamilton syringe loaded with 4 μl of 
the 6-OHDA (8 μg/4 μL dissolved in 0.2% ascorbic acid; Sigma, Sigma-Aldrich, United States) or 
saline solution was lowered 8.4 mm below the skull (Paxinos and Watson, 1986, Kang et al., 2016, 
Ndlovu et al., 2016). The 6-OHDA solution or 0.9% saline was unilaterally infused at a rate of 1 μL per 
minute. In total the needle was left inside the brain for 6 minutes allowing for the diffusion of the 6-
OHDA or 0.9% saline solution into the surrounding tissue after which the needle was slowly retracted 
(Mabandla et al., 2015). 
  
5.4 Animal grouping  
The SD rats were divided into two phases which define the overall study design, the pre-LID and the 
LID phase. The groups in the pre-LID phase comprised of the rats that were treated for 14 days. The 
first day of treatment was 7 days post-surgery. Saline-lesioned rats were handled for 14 days and served 
as the negative control (Sal (14)) group, while the 6-OHDA-lesioned rats were further divided into two 
groups. The 6-OHDA-lesioned rats that received a subcutaneous injection (s.c) of saline for 14 days 
served as the positive control (6-OHDA (14)). The other 6-OHDA-lesioned group received a s.c with a 
combination of L-DOPA (50 mg/kg) and benserazide (10 mg/kg) for 14 days, which served as the test 
group (L-DOPA (14)). The LID phase groups comprised of SD rats that received treatment for 28 days. 
Saline-lesioned rats were handled for 28 days and served as a negative control (Sal (28)). The 6-OHDA-
lesioned rats that received a s.c of saline for 28 days served as the positive control (6-OHDA (28)) and 
the remaining 6-OHDA-lesioned received s.c with a combination of L-DOPA (50 mg/kg) and 
benserazide (10 mg/kg) for 28 days, which served as the test group (L-DOPA (28)) (figure 9). 
 
5.5 L-DOPA treatment 
Seven days after the surgery, L-DOPA (50 mg/kg; Sigma, Sigma-Aldrich, United States), combined 
with the peripheral DOPA–decarboxylase inhibitor, benserazide (10 mg/kg; Sigma, Sigma-Aldrich, 
United States), was dissolved in 0.9% saline (Huang et al., 2011). Benserazide was administered to 
reduce the metabolism of L-DOPA in the periphery. The drugs were administered twice daily (9 am 
and 4 pm) for 14 days (pre-LID phase) or 28 days (LID phase). 
 
5.6 Abnormal involuntary movement scoring 
Abnormal involuntary movements (AIMs) were scored daily between 9 am, and 10 am from the 21st 
day of L-DOPA injection (Ndlovu et al., 2016). On the day of observation, the rats were individually 
placed in transparent empty plastic cages 10 min before drug administration. Fifteen minutes after the 
drug administration, each rat was observed for 60 minutes for AIMs scoring. The AIMs scoring was 
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done for the last eight days of the 28-day treatment. The AIMs being observed and scored were A) axial 
dystonia (contralateral twisted posturing of the neck and upper body), (B) abnormal orolingual 
movements (stereotyped jaw movements and contralateral tongue protrusion) and (C) abnormal 
forelimb movements (repetitive rhythmic jerks or dystonic posturing of the contralateral forelimb and 
grabbing movements of the contralateral paw) (Ostock et al., 2011). The severity of the three AIMs 
were rated from 0 to 4, where 0 denotes the absence of AIMs, 1 represents occasional occurrence, 2 
represents frequent occurrence, 3 represents uninterrupted occurrence, and  4 means that the dyskinetic 
behaviour was continuous and not interrupted by sensory distraction (Ndlovu et al., 2016). Total AIMs 
were determined from each rat's total scores, which were averaged to determine the group total, and 
reported (Ndlovu et al., 2016).  
 
5.7 Euthanasia 
The rodents were brought to the autopsy suite an hour before decapitation. The rats were decapitated 
using a guillotine at 12 pm, and trunk blood was collected in EDTA coated blood vails; after 
centrifugation for ~5 minutes, the plasma collected and stored at -80°C for further analysis. The 
cerebella and the striata from the rodent's brain were collected in Eppendorf tubes. The tissue was then 
snap-frozen in liquid nitrogen and stored at -80°C for further analyses (figure 9).  
 
5.8 Neurochemical analysis  
5.8.1 Tumour necrosis factor-alpha ELISA assay 
Frozen striatal/cerebella tissue samples were thawed at room temperature. A competitive ELISA kit 
from Elabscience science (Biocom Africa (Pty) Ltd, South Africa) was used to determine the 
concentration of TNF-α, as per the manufacturer's guidelines. The tissue samples were minced and 
washed using iced-cold PBS to remove excess blood. The tissue samples were homogenised in PBS 
buffer (1 g of tissue: 9 mL of PBS) and further centrifuged at 5000 ×g for 5 minutes. The supernatant 
was collected, and the standards and other reagents were prepared separately. The standard solution 
(100 µL) was added to each well in the first two columns of the 96 well plate. The samples (100 µL) 
were added to the remaining wells. The sealed plate was incubated at 37℃ for 90 minutes. The liquid 
in the plate was decanted, and Biotinylated Detection Ab working solution (100 µL) was added to the 
wells. The sealed plate was incubated at 37℃ for 60 minutes. The solution was decanted, and the plate 
washed using the wash buffer. The HRP Conjugate working solution was added to each well, the plate 
sealed and incubated at 37oC for 30 minutes. The plate was then decanted and washed using the wash 
buffer and plate washer. Substrate Reagent was added into each well; the plate was sealed and incubated 
for 15 minutes at 37℃. Stop solution (50 µL) was added to each well, and the optical density 





5.8.2 Dopamine ELISA assay 
Frozen striatal/cerebella tissue samples were left on the benchtop, allowing it to thaw at room 
temperature. A competitive ELISA kit from Elabscience science (Biocom Africa (Pty) Ltd, South 
Africa) was used to determine the concentration of dopamine (DA). This assay was executed according 
to the manufacturer's guidelines. The tissue samples were minced and washed using iced-cold PBS to 
remove excess blood. The tissue samples were homogenised in PBS buffer (1 g of tissue: 9 mL of PBS) 
and further centrifuged at 5000 ×g for 5 minutes. The supernatants were collected; standards and other 
reagents were prepared separately. The standard working solutions (50 µL) were added to the first two 
strips of the antibody-coated 96 well plate, and the sample homogenates (50 µL) were added to the 
remaining wells. Immediately after, 50 µL of Biotinylated Detection solution was added to each well. 
The plate was sealed and incubated for 45 minutes at 37℃. The solution was decanted, and the plate 
washed using the wash buffer. HRP Conjugate working solution (100 µL) was added to each well. The 
plate was sealed and incubated for 30 minutes at 37℃. The plate was then decanted and washed using 
the wash buffer and plate washer. Substrate Reagent was added into each well. The sealed plate was 
incubated for 15 minutes at 37℃. Stop Solution (50 µL) was added to each well. Stop solution (50 µL) 
was added to each well, and the optical density immediately determined using the SPECTROstarNANO 
micro-plate reader (BMG LABTECH) set to 450 nm.   
 
5.8.3 Reverse transcription-polymerase chain reaction 
5.8.3.1 RNA extraction  
The extraction process was performed in three steps: homogenisation of tissue, clearing, and RNA 
purification. The RNA extraction was done using the Zymo Research's Quick-RNA Miniprep kit 
(Inqaba Biotechnical Industries (Pty) Ltd, South Africa), following the manufacturer's guidelines. 
Frozen striata tissue samples were homogenised in RNA lysis buffer.  The homogenates were 
centrifuged for 1 minute at 10000 xg, and the supernatants were further filtered, and the flow-through 
was saved. Absolute ethanol (95-100%) was added to the sample (1 mL of lysis buffer: 1 mL of 
ethanol). The mixture was filtered, and the flow-through was discarded. RNA Prep Buffer (400 µL) 
was added to the Spin-Away filters in collection tubes, and the tube was centrifuged for half a minute. 
The filtrate was kept, and the flow-through was discarded. The RNA wash buffer was added to the 
filter tube and centrifuged for 2 minutes at 10000 xg. The filter tubes were placed in RNase free tubes 
and 100 µL DNase/RNase-Free water was added into the filter tubes and centrifuged for 30 seconds.   
 
5.8.3.2 cDNA synthesis 
Synthesis of cDNA was done using the BioLabs Inc. ProtoScript II First-strand cDNA synthesis kit 
(Inqaba Biotechnical Industries (Pty) Ltd, South Africa). This procedure was done following the 
manufacturer's guidelines. The cDNA synthesis reaction components were as follows: extracted RNA 
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(1 µg), 2 µL of d(T)23 VN, 10 µL of ProtoScript II Reaction Mix, 2 µL of ProtoScript II Enzyme Mix 
(10X) and nucleases-free water was added to make a final volume of 20 µL in a 0.2 mL tube. The 
reaction components were briefly mixed, and the tubes were incubated for 60 minutes at 42℃, and the 
enzyme was inactivated at 80℃ for 5 minutes.   
 
5.8.3.3 Gene expression  
The primers used in this experiment were prepared by Inqaba Biotechnical Industries (Pty) Ltd, South 
Africa. The reference gene used is glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The forward 
and revise primer sequences that were used to amplify the expression of GAPDH and D2R are in table 
1. The cDNA (5 µL) sample was used as a template for PCR amplification using Luna Universal qPCR 
Master Mix (Inqaba Biotechnical Industries (Pty) Ltd, South Africa) as a fluorophore. The real-time 
PCR detection system used was the LightCycler® 96 Instrument (Roche Life Science, South Africa). 
The reaction had a denaturation and polymerase activation procedures for 30 seconds at 95℃ and 
amplification process comprising of denaturation for 15 seconds at 95℃ and annealing for 60 seconds 
at 60℃ for 40 cycles. The system read the plate at 60℃, and the LightCycler® 96 software (Roche Life 
Science, South Africa) was used to analyse the data collected. The ΔΔCq method was used to compare 
the expression of the reference gene to the expression of D2R. 
 
Table 1: The primers sequences for D2R, and GAPDH that were used in the present study 
 
Primer Forward primer  Reverse primer 
D2R 5’-CAA-CAA-TAC-AGG-CAA-ACC-AGA-
ATG- AG- 3’ 
5’-ACC-AGC-AGA-GTG-ACG-ATG-AAG- 
G-3’ 
GAPDH 5’-GCG-AGA-TCC-CGT-CAA-GAT-CA-3’ 5’-CCA-CAG-TCT-TCT-GAG-TGG-CAG-3’ 
 
5.8.4 Acetylcholinesterase ELISA assay 
Frozen striata tissue samples were thawed at room temperature. A competitive ELISA kit from 
Elabscience science (Biocom Africa (Pty) Ltd, South Africa) was used to determine the concentration 
of AChE, following the manufacturer's guidelines. The tissue was minced and washed using iced-cold 
PBS to remove excess blood. The tissue samples were homogenised in PBS buffer (1 g of tissue: 9 mL 
of PBS) and further centrifuged at 5000 ×g for 5 minutes. The supernatant was collected, and the 
standards and other reagents were prepared separately. The standard solution (100 µL) was added to 
each well in the first two columns of the 96 well plate. The samples (100 µL) were added to the 
remaining wells. The sealed plate was incubated at 37℃ for 90 minutes. The liquid in the plate was 
decanted, and Biotinylated Detection Ab working solution (100 µL) was added to the wells. The sealed 
plate was incubated at 37℃ for 60 minutes. The solution was decanted, and the plate washed using the 
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wash buffer. The HRP Conjugate working solution was added to each well, the plate sealed and 
incubated at 37oC for 30 minutes. The plate was decanted and the plate washed using the wash buffer. 
The substrate solution (90 µL) was added to each well; the plate was sealed and incubated at 37oC for 
15 minutes.  Stop solution (50 µL) was added to each well, and the optical density immediately 
determined using the SPECTROstarNANO micro-plate reader (BMG LABTECH) set to 450 nm.  
 
5.9 Statistical analysis  
The statistical software GraphPad Prism version 7 (GraphPad Software Inc, United States) was used to 
analyse the data. Shapiro-Wilk normality test was used to ascertain the distribution of the data. The 
two-way analysis of variance followed by the Sidak's multiple comparisons test was used to analyse the 
behavioural tests' data. One-way analysis of variance plus Tukey's multiple comparisons test was used 
to examine the neurochemical results. All the data were expressed as standard error of the mean, and a 
p-value of less than 0.05 was considered significant. 
 
Table 2: Showing the symbols that will be used to describe the p-values obtained in the multiple 
comparison test   
Symbol  p-value 
* 0.01 ≥ p < 0.05 
** 0.001 ≥ p < 0.01 
*** 0.0001 ≥ p < 0.001 
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ELISA Assay → TNF-α (striata and cerebella), DA (Striata) and AChE (striata) 




Figure 9: Illustrates the study design and timeline for the induction of parkinsonism in SD rats and the 
treatment using L-DOPA. 
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Previous studies showed that reduced DA signalling plays a significant role in the development of both 
motor and cognitive deficits in PD. The unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial 
forebrain bundle has been shown to reduce DA signalling in the striatum, hippocampus, amygdala and 
the PFC. The reduced DA signalling and other molecular dysfunction in these brain areas have been 
associated with cognitive decline. The treatment with L-DOPA improves DA signalling in the brain 
and has been shown to alleviate some cognitive deficit. Still, other studies have also reported L-DOPA's 
detrimental effects on cognition. The present study investigates how chronic L-DOPA treatment affects 
spatial learning, spatial memory, and recognition memory. 
 
The alteration of prefrontal cortex D1 receptor expression as abnormal involuntary movement 
develops in a rat model of L-DOPA induced dyskinesias.  
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L-3,4-dihydroxyphenylalanine (L-DOPA) increases dopamine (DA) signalling and has been shown to 
ease some of the cognitive difficulties caused by Parkinson’s disease (PD). The present study 
investigates how chronic L-DOPA treatment affects spatial learning, spatial memory, and recognition 
memory. The Morris water maze test and the novel object recognition test were used to assess cognitive 
function. The concentration of tumour necrosis factor-alpha (TNF-α), corticosterone, 
acetylcholinesterase (AChE), and DA were quantified along with dopaminergic D1 receptor (D1R) 
expression. The results showed that a unilateral 6-OHDA lesion resulted in impaired spatial learning, 
spatial memory, and object recognition memory. Treatment with L-DOPA did not improve object 
recognition memory. However, L-DOPA treatment for 14 days improved spatial learning and memory, 
but spatial memory was impaired when the treatment was prolonged for 28 days. There was a 
significantly increased concentration of TNF-α in the prefrontal cortex (PFC), plasma corticosterone, 
hippocampal AChE, and upregulated D1R expression in 6-OHDA lesioned rats. The treatment with L-
DOPA significantly reduced the concentration of TNF-α in the prefrontal cortex, plasma corticosterone, 
hippocampal AChE, and D1R expression in the PFC but increased PFC DA and AChE concentration. 
There were cognitive deficits induced by the 6-OHDA lesion, but L-DOPA was only able to improve 
spatial learning and memory. However, prolonged treatment failed to improve 6-OHDA induced spatial 
memory impairment. This resulted from heightened AChE concentration in both the hippocampus and 
PFC that persisted since L-DOPA was able to ameliorate imbalances in the HPA axis, 
neuroinflammation in the PFC, and maintained DA signalling. 
 
Keywords: Parkinson ‘s disease, dopamine, tumour necrosis factor-alpha, acetylcholinesterase, and 6-




Parkinson's disease (PD) is a disorder that is characterised by motor symptoms that result from the loss 
of dopaminergic neurons specifically in the nigrostriatal pathway (German et al., 1989, Gibb and Lees, 
1991). PD's hallmark features are motor symptoms, but PD also prevails with non-motor symptoms, 
including cognitive deficits (Baggio et al., 2014, Zis et al., 2015, Yang et al., 2016). Studies have shown 
that PD patients present with cognitive deficits even in the early stages of the disease (Dubois and 
Pillon, 1996, Baggio et al., 2015). The incidences of cognitive deficits in PD increases from 10% to 
80% from early to advanced stages of the disease (Williams-Gray et al., 2007, Hely et al., 2008). 
Cognitive deficits associated with PD include impaired visuospatial learning, spatial recognition 
memory, attention deficiencies and others (Muslimović et al., 2005, Paolo et al., 2011, Amboni et al., 
2015). The development of cognitive deficits in PD patients depend on several factors, including the 
age of disease onset (Muslimović et al., 2005, Babiloni et al., 2019). 
 
Studies have reported cognitive decline while others showed no deviation in cognitive behaviours 
(Miyoshi et al., 2002, Braga et al., 2005, Branchi et al., 2008). The unilateral lesion into the medial 
forebrain bundle (MFB) has been shown to induce memory impairment showing that dopamine (DA) 
depletion may play a role in the cognitive decline evident in PD (Tadaiesky et al., 2008, Du et al., 2018). 
The lesion in the MFB is thought to reduce DA signalling in the prefrontal cortex and hippocampus, 
two areas that play a crucial role in cognition (Du et al., 2018). DA signalling is dependent on DA 
receptors, especially DA D1 receptor (D1R), which is thought to modulate aspects of cognition (Song 
et al., 2016, Meltzer et al., 2019). This receptor is highly expressed in the PFC, striatum, and 
hippocampus of PD patients in response to low DA signalling (Ledonne and Mercuri, 2017).  
 
The excitatory neurotransmitter acetylcholine (ACh) can also stimulate DA release via nicotinic and 
muscarinic receptor present on DA neurons (Kharkwal et al., 2016). However, the presence of DA D2 
receptor on ACh neurons, which stimulated the release of ACh, shows that both neurotransmitters have 
a feedback mechanism (Kharkwal et al., 2016). ACh may play a vital role in the cognitive deficits in 
PD since ACh alterations in the hippocampus, and the PFC have been associated with cognitive decline 
(Tzavara et al., 2003, Croxson et al., 2011). ACh's function is also regulated by acetylcholinesterase 
(AChE), an enzyme that hydrolysis ACh to acetate and choline (Bourne et al., 2003, Maiti et al., 2017). 
Reduced DA signalling such as in PD, distorts cholinergic signalling, which would impair cognitive 
function (Ngoupaye et al., 2018). L-DOPA treatment may improve ACh signalling and, therefore, 
improve cognitive skills in PD patients (Toyoda, 2018). Another factor that may lead to cognitive 
deficits in PD is a hyperactive hypothalamic-pituitary-adrenal axis which results in an increased 
secretion of cortisol in humans and corticosterone in rodents (Hartmann et al., 1997, Ngema and 
Mabandla, 2017). Glucocorticoids like corticosterone in high concentration have a neurotoxic effect 
which can play a crucial role in exacerbating the rate of DA neuron degeneration in PD (Kibel and 
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Drenjančević-Perić, 2008). The elevated glucocorticoid levels promote the release of pro-inflammatory 
cytokines (Shini et al., 2010). In addition to high glucocorticoids, the death of DA neurons stimulates 
an immune response, propagated by pro-inflammatory cytokines like tumour necrosis factor-alpha 
(TNF-α) (Mogi et al., 1994, Jin et al., 2008, Tufekci et al., 2012). The increased secretion of these 
cytokines is associated with higher oxidative stress, leading to the death of DA neurons (Boka et al., 
1994, Tufekci et al., 2012).  
 
Standard treatment for PD patients remains the DA precursor, L-3,4-dihydroxyphenylalanine (L-
DOPA) which increases DA signalling and is, therefore, able to ameliorate the motor symptoms 
characteristic of PD (Gotham et al., 1988, Kulisevsky et al., 1996). Continual use of L-DOPA usually 
results in abnormal motor fluctuations called L-DOPA induced dyskinesias (LIDs) (Ndlovu et al., 
2016). In some studies with L-DOPA as a treatment for PD, there was a significant improvement in the 
cognitive deficits associated with PD (Celesia and Wanamaker, 1972, Gul and Yousaf, 2018).  
However, other findings showed that L-DOPA therapy does not improve episodic, spatial learning and 
spatial memory in PD (Hietanen and Teräväinen, 1988, Gevaerd et al., 2001). The above is possibly 
due to dopamine influx to cortical areas related to cognitive function (Swainson et al., 2003, Cools, 
2006, Ko et al., 2016). L-DOPA therapy's effect on cognitive function is still not apparent because 
although it can remediate some cognitive deficits, it can also induce non-motor fluctuations with 
cognitive dysfunction and neuropsychiatric symptoms (Calabresi et al., 2015). The present study 
investigates how the development of abnormal involuntary movements (AIMs) affects spatial learning, 
spatial memory, and episodic memory during L-DOPA treatment. Understanding the alteration of D1 
and AChE in the different PD stages could provide the knowledge required to develop preventative or 
more effective treatments as PD progresses. 
 
2. Materials and methods 
2.1 Animal Care and Housing  
All the experimental procedures in the present study were approved by the University of KwaZulu-
Natal's Animal Research Ethics Committee (AREC/077/018M). Male Sprague Dawley rats weighing 
220 -250 g were obtained from Biomedical Resource Unit of the University of KwaZulu-Natal. The 72 
rats were housed in clear polycarbonate cages in the holding area during the study. The holding area 
was kept under standard laboratory conditions: 22 +/-1oC room temperature, 50 - 70% humidity, and a 
12h light/dark cycle with lights on at 06h00.  The rats were given seven days to acclimatise to the 




2.2 Stereotaxic surgery  
The combination of Ketamine (125 mg/kg) and xylazine (10 mg/kg) was used as anaesthesia (Veilleux-
Lemieux et al., 2013). Ketamine keeps the rat unconscious, and xylazine increased the heart rate to 
prevent low blood pressure during surgery (Bennett and Bullimore, 1973, Veilleux-Lemieux et al., 
2013). The Hamilton syringe was loaded with 4 μL of the 6-hydroxydopamine (6-OHDA) solution (8 
μg/4 μL dissolved in 0.2% ascorbic acid; Sigma, Sigma-Aldrich, United States) or saline and mounted 
on the stereotaxic frame (David Kopf Instruments, Tujunga, USA). The anaesthetic was administered 
via intraperitoneal injection before surgery. The unconscious rats were placed into the stereotaxic frame, 
and a small hole was drilled at the following coordinates from the lambda 4.7 mm anterior and -1.6 mm 
from the midline  (Paxinos and Watson, 1986). The Hamilton syringe was then lowered 8.4 mm below 
the skull, and the 6-OHDA solution or 0.9% saline was released at a rate of 1 μL per minute. The syringe 
was left in place for 6 minutes to allow the 6-OHDA to diffuse into the surrounding tissue after which 
the needle was slowly retracted (Mabandla et al., 2015). The rats were given 7 days to recover from the 
surgery. 
  
2.3 Animal grouping 
The rats were divided into 2 timelines, the pre-LID and the LID timeline. In the first timeline, the rats 
were sacrificed after 14 days of handling, subcutaneous saline injections, or L-DOPA treatment. The 
negative control (Sal (14)) consists of rats that were intracranially injected with 0.9% saline and 
handled for 14 days. The positive control group (6-OHDA (14)) consists of rats lesioned with 6-
OHDA solution and were subcutaneously injected with 0.9% saline for 14 days. The test group (L-
DOPA (14) comprised of rodents that were lesioned with 6-OHDA and later treated with L-DOPA. 
The LID timeline consisted of rats sacrificed after 28 days of handling, subcutaneous saline injections, 
or L-DOPA treatment. The negative control (Sal (28)) consists of rats that were intracranially injected 
with 0.9% saline and handled for 28 days. The positive control group (6-OHDA (28)) consists of rats 
lesioned with 6-OHDA solution and were subcutaneously injected with 0.9% saline for 28 days. The 
test group (L-DOPA (28) comprised of rats that were lesioned with 6-OHDA solution and treated with 
L-DOPA for 28 days. 
 
2.4 L-DOPA treatment and administration schedule   
A combination of L-DOPA (50 mg/kg s.c; Sigma, Sigma-Aldrich, United States) combined with the 
peripheral DOPA–decarboxylase inhibitor, benserazide (10 mg/kg s.c; Sigma, Sigma-Aldrich, United 
States), was dissolved in 0.9% saline (Huang et al., 2011). The drug was administered seven days after 




2.5 Behavioural tests  
2.5.1 Novel object recognition test   
The novel object recognition test (NORT) was conducted to assess a rodent's recognition memory, 
determined by the rodent's exploratory behaviour. The test is based on the rodent's tendency to study a 
novel object more than an object it has encountered. This test comprises of 3 stages: habituation, 
familiarisation, and the final test (Batool et al., 2016). The rats were given 3 days (figure 1) to get 
habituated to being in the square wooden box (100×100×50 cm). On the 4th day (figure 1), the two 
identical objects were placed in the wooden box so that the rats could study the objects for 5 minutes. 
The test stage commenced an hour after the familiarisation stage. In the final stage, one of the familiar 
objects was replaced by the novel object and the animals were given 5 minutes to explore the objects. 
The exploratory behaviour was recorded, i.e., the time the animals spent exploring the familiar object 
(F) and the time the rats spent exploring novel objects (N) (Ngoupaye et al., 2018). Intact recognition 
memory is evidenced by subjects spending more time investigating the novel object. A discrimination 
index (DI) defined as (N - F)/(N + F) was calculated for each animal (Ngoupaye et al., 2017).  
 
2.5.2 Morris water maze test  
Morris water maze test (MWMT) was used to assess spatial learning and memory. The MWMT 
apparatus is an open circular 1 m diameter pool with a black interior that is half-filled with water with 
a small transparent escape platform hidden inside. Two lines perpendicular to each other, divide the 
maze into four quadrants and visual cues will be placed inside each of the quadrants. The MWMT 
comprises two stages: the learning stage, which lasted for 3 days and the probe stage in 1 day (figure 
1). During the learning stage of the MWMT, the rats were trained to find a submerged platform that 
was placed in one of the quadrants (target quadrant) (D’Hooge and De Deyn, 2001). The rats were 
trained to find the hidden platform using distal visual cues on the maze wall. The time taken by the rats 
to find the hidden platform was recorded. The time it took the rats to find the platform was used as an 
indication of spatial learning. The probe stage is a post-test for learning that measures an animal's ability 
to remember the target quadrant. The time the rodent spent in the target quadrant is deemed the measure 
of the rats' ability to remember or spatial memory (Cassim et al., 2015). 
  
2.6 Euthanasia  
Twelve rats per group were sacrificed on the 14th and 28th day of treatment or handling. The rats were 
decapitated using a guillotine and trunk blood, and brain tissue was collected. The blood was collected 
in EDTA coated tubes and centrifuged for 5 minutes at 5000 ×g. The isolated plasma was transferred 
to Eppendorf tubes and stored at -80°C for further analysis. The brain was dissected, and the prefrontal 
cortex (PFC) and hippocampus were collected and stored at -80°C for further analysis. 
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2.7 Neurochemical analysis    
2.7.1 Tumour necrosis factor-alpha ELISA kit 
A sandwich ELISA kit from Elabscience science (Biocom Africa (Pty) Ltd, South Africa) was used to 
determine the concentration of Tumour necrosis factor-alpha (TNF-α) in PFC samples. This process 
was done according to the manufacturer's guideline. Frozen rat PFC tissue was taken out of the bio-
freezer and placed on ice, allowing it to defrost before use. The defrosted tissues were washed in PBS 
buffer to remove excess blood. Homogenisation of the tissue samples occurred in PBS buffer (1 g of 
tissue: 9 mL of PBS) after which the homogenate was centrifuged at 5000 ×g for 5 minutes. The 
standard and other reagents from the ELISA kit were prepared as per the manufacturer's guidelines. The 
supernatant was collected from the centrifuged homogenate and placed in Eppendorf tubes. A sealed 
96 well plate was provided in the kit, and a 100 µL of the standard solutions were added to the wells in 
the first two columns with the blanks in the bottom two wells. A 100 µL of the supernatant samples 
were added to the remaining wells, and the plate was sealed and incubated at 37℃ for 90 minutes. The 
solution in the plate was decanted, then a 100 µL Biotinylated Detection Ab working solution was added 
to each well. The plate was incubated at 37℃ for 60 minutes. The wells' solution was decanted, and the 
plate washed three times using the provided wash buffer. Avidin-Horseradish Peroxidase conjugate 
working solution (100 µL) was added to each well; the plate was sealed and incubated at 37℃ for 30 
minutes. The solution in the plate was decanted and washed five times. The substrate solution (90 µL) 
was added to each well, and the plate was sealed and incubated at 37℃ for 15 minutes.  The stop 
solution (50 µL) was added to each well, and the optical density of the solution in each well was 
determined using the SPECTROstarNANO micro-plate reader (BMG LABTECH) set to 450 nm. 
 
2.7.2 Corticosterone ELISA kit 
A competitive ELISA kit from Elabscience science (Biocom Africa (Pty) Ltd, South Africa) was used 
to determine plasma corticosterone concentration. This process was executed according to the 
manufacturers' guideline. The collected plasma was centrifuged 15 minutes at 1000 ×g at 4℃. The 
plasma, standards, and other reagents were prepared according to the manufacturers' guidelines. A 
sealed 96 well plate was provided in the kit, and 50 µL of the standard solutions were added to the wells 
in the first two columns with the blanks in the bottom two wells.  The plasma samples' supernatants 
were added to the remaining wells, then Biotinylated Detection Ab working solution (50 µL) was added 
to all the wells. The plate was sealed and incubated for 45 minutes at 37℃. The solution was decanted 
from the plate; then it was washed three times using the ELISA kit's wash buffer. Avidin-Horseradish 
Peroxidase conjugate working solution (100 µL) was added to each well; the plate was sealed and 
incubated at 37℃ for 30 minutes. The solution was decanted, and the plate was washed five times. The 
substrate solution (90 µL) was added to each well; the plate was sealed and incubated at 37℃ for 15 
minutes.  The stop solution (50 µL) was added to each well, and the optical density of the solution in 
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each well was determined using the SPECTROstarNANO micro-plate reader (BMG LABTECH) set to 
450 nm. 
 
2.7.3 Acetylcholinesterase ELISA kit 
A sandwich ELISA kit from Elabscience science (Biocom Africa (Pty) Ltd, South Africa) was used to 
determine the concentration of acetylcholinesterase (AChE) in the PFC or hippocampal tissue samples. 
This process was done according to the manufacturer's guideline. Frozen rat PFC or hippocampal tissue 
samples were taken out of the bio-freezer and placed on ice, allowing it to defrost before use. The 
defrosted tissues were washed in PBS buffer to remove excess blood. Homogenisation of the tissue 
samples occurred in PBS buffer (1 g of tissue: 9 mL of PBS) after which the homogenate was 
centrifuged at 5000 ×g for 5 minutes. The standard and other reagents from the ELISA kit were prepared 
as per the manufacturer's guidelines. The supernatant was collected from the centrifuged homogenate 
and placed in Eppendorf tubes. A sealed 96 well plate was provided in the kit, and a 100 µL of the 
standard solution was added to the wells in the first two columns with the blank in the bottom two wells. 
A 100 µL of the supernatant samples were added to the remaining wells, and the plate was sealed and 
incubated at 37℃ for 90 minutes. The solution in the plate was decanted, then a 100 µL biotinylated 
Detection Ab working solution was added to each well. The plate was incubated at 37℃ for 60 minutes. 
The wells' solution was decanted, and the plate washed three times using the provided wash buffer. The 
Avidin-Horseradish Peroxidase conjugate working solution was added to each well; the plate was sealed 
and incubated at 37℃ for 30 minutes. The solution in the plate was decanted and washed five times. 
The substrate solution (90 µL) was added to each well; the plate was sealed and incubated at 37℃ for 
15 minutes.  The stop solution (50 µL) was added to each well, and the optical density of the solution 
in each well was determined using the SPECTROstarNANO micro-plate reader (BMG LABTECH) set to 
450 nm. 
 
2.7.4 Dopamine ELISA kit 
A competitive ELISA kit from Elabscience science (Biocom Africa (Pty) Ltd, South Africa) was used 
to determine the concentration of dopamine (DA) in the PFC tissue samples. This process was done 
according to the manufacturer's guidelines. Frozen rat PFC tissue samples were taken out of the bio-
freezer and placed on ice, allowing it to defrost before use. The defrosted tissues were washed in PBS 
buffer to remove excess blood. Homogenisation of the tissue samples occurred in PBS buffer (1 g of 
tissue: 9 mL of PBS) after which the homogenate was centrifuged at 5000 ×g for 5 minutes. A sealed 
96 well plate was provided in the kit, and 50 µL of the standard solutions were added to the wells in the 
first two columns with the blanks in the bottom two wells.  The samples' supernatants were added to 
the remaining wells, then Biotinylated Detection Ab working solution (50 µL)was added to all the wells 
on the plate. The plate was sealed and incubated for 45 minutes at 37℃. The solution was decanted 
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from the plate. Then it was washed three times using the wash buffer provided in the ELISA kit. Avidin-
Horseradish Peroxidase conjugate working solution (100 µL) was added to each well; the plate was 
sealed and incubated at 37℃ for 30 minutes. The solution was decanted, and the plate was washed five 
times. The substrate solution (90 µL) was added to each well; the plate was sealed and incubated at 
37℃ for 15 minutes.  The stop solution (50 µL) was added to each well, and the optical density of the 
solution in each well was determined using the SPECTROstarNANO micro-plate reader (BMG 
LABTECH) set to 450 nm. 
  
2.7.5 Reverse transcription-polymerase chain reaction 
This process is divided into three main steps ribose nucleic acid (RNA) extraction, cDNA synthesis, 
and polymerase chain reaction (PCR). The RNA extraction was done using the Zymo Research's Quick-
RNA Miniprep kit (Inqaba Biotechnical Industries (Pty) Ltd, South Africa) from crushed PFC tissue 
samples. The extracted RNA (1 µg) was used as a template to make complementary dihydroxy ribose 
nucleic acid (cDNA) using the BioLabs Inc. ProtoScript II First-strand cDNA synthesis kit (Inqaba 
Biotechnical Industries (Pty) Ltd, South Africa). Dopamine type 1 receptor (D1R) and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) genes were amplified using the Luna Universal qPCR Master 
Mix (Inqaba Biotechnical Industries (Pty) Ltd, South Africa). The forward and revise primer sequences 
that were used for the amplification of GAPDH and D1R are in table 1, below. The primers used in this 
experiment were prepared by Inqaba Biotechnical Industries (Pty) Ltd, South Africa. The real-time PCR 
system used was the LightCycler® 96 Instrument (Roche Life Science, South Africa). The reaction had 
a denaturation and polymerase activation procedures for 30 seconds at 95℃ and amplification process 
comprising of denaturation for 15 seconds at 95℃ and annealing for 60 seconds at 60℃ for 40 cycles. 
The system read the plate at 60℃, and the LightCycler® 96 software (Roche Life Science, South 
Africa) was used to analyse the data collected. The ΔΔCq method was used to compare the expression 
of the reference gene to the expression of D1R. 
 
Table 1: The primers sequence for D1R and GAPDH that were used in the present study (de Souza et 
al., 2018) 
Primer Forward primer  Reverse primer 
D1R 5’-CTG-GAG-GAC-ACC-GAG-GAT-GAC-3’ 5’-GTC-GAT-GAG-GGA-CGA-TGA-AAT -
GG -3’ 
GAPDH 5’-GCG-AGA-TCC-CGT-CAA-GAT-CA-3’ 5’-CCA-CAG-TCT-TCT-GAG-TGG-CAG-3’ 
 
2.8 Statistical Analysis  
The collected data were analysed using GraphPad Prism version 7 software (GraphPad Software Inc, 
United States). The Shapiro-Wilk normality test was used to ascertain data distribution. One-way 
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analysis of variance was used to analyse the data followed by Tukey's multiple comparisons test to 
determine the differences between individual groups. A p< 0.05 is considered statistically significant. 
The data were expressed as mean± SEM.  
Table 2: Shows the symbols that will be displayed in the graphs to describe the p-values obtained in 
the multiple comparison test  
Symbol  p-value 
* 0.01 ≥ p < 0.05 
** 0.001 ≥ p < 0.01 
*** 0.0001 ≥ p < 0.001  






















Figure 1: The study design and the timeline for the treatment of L-DOPA.   
Male Sprague Dawley rats from BRU (n=72) 
Rats were given 7 days of acclimatization and were then randomly separated. 
Stereotaxic surgery/ Lesioning. Day 0 





First day of treatment either handling, saline (sc) or a combination of L-DOPA and benserazide (sc).  
Day 8 






















(L-DOPA +Benserazide (sc)) 
NORT and MWMT. Day 15-20 
ELISA Assay → TNF-α (PFC), DA (PFC), AChE (PFC and hippocampus) and corticosterone (plasma) 
RT-PCR → D1 receptor expression (striata) 
(n=3/group) 
SD Rats were sacrificed → plasma, PFC and 
hippocampus tissues was collected and Snap frozen in 
liquid nitrogen. 
 
The collected samples were stored in a bio-freezer at -
80˚C for neurochemical analysis. 
Day 21 
 
SD Rats were sacrificed → plasma, PFC and 
hippocampus tissue was collected and Snap frozen in 
liquid nitrogen. 
 
The collected samples were stored in a bio-freezer at -






3.1 Novel object recognition test  
The recognition memory of the SD rats was assessed in the following groups: Sal (14), 6-OHDA (14), 
L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 2. The discrimination index was 
significantly reduced in the groups lesioned with 6-OHDA (Sal (14) vs 6-OHDA (14); F5, 60 = 
15.38, p = 0,0012, figure 2), (Sal (14) vs L-DOPA (14); F5, 60 = 15.38, p = 0,0001, figure 2), (Sal 
(28) vs 6-OHDA (28); F5, 60 = 15.38, p = 0,0001, figure 2), and (Sal (28) vs L-DOPA (28); F5, 60 = 
15.38, p = 0,0011, figure 2). There was a L-DOPA effect present when comparing the untreated and 
treated 6-OHDA lesioned groups after 14 days of treatment (6-OHDA (14) vs L-DOPA (14); F5, 12 = 












































































































Figure 2: Graph showing the discriminatory index as assessed using the NORT (n=11 per group). 
 
3.2 Morris water maze test 
3.2.1 Spatial learning 
Spatial learning was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), Sal (28), 
6-OHDA (28), and L-DOPA (28), figure 3. There was a 6-OHDA effect in finding the hidden platform 
(Sal (14) vs 6-OHDA (14); F5, 60 = 75.42, p<0.0001, figure 3) and (Sal (28) vs 6-OHDA (28); F5, 60 
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= 75.42, p<0.0001, figure 3). L-DOPA treatment attenuated the 6-OHDA effect (6-OHDA (14) vs L-
DOPA (14); F5, 60 = 75.42, p<0.0001, figure 3) and (6-OHDA (28) vs L-DOPA (28); F5, 60 = 75.42, 
p<0.0001, figure 3). 
























































































* * * * * * * *
* * * * * * * *
 
 
Figure 3: Shows the time taken for the rats to find the submerged platform during the third day of 
training in the MWMT (n=11 per group). 
 
3.2.2 Spatial memory  
Spatial memory of the SD rats was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA 
(14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 4. A 6-OHDA effect was observed in the time 
spent in the target quadrant (Sal (14) vs 6-OHDA (14); F5, 60 = 48.84, P<0.0001, figure 4) and (Sal 
(28) vs 6-OHDA (28); F5, 60 = 48.84, P<0.0001, figure 4). This effect was ameliorated in the group 
treated with L-DOPA for 14 days (6-OHDA (14) vs L-DOPA (14); F5, 60 = 48.84, P<0.0001, figure 
4). However, L-DOPA treatment did not lessen the effects of 6-OHDA following 28 days of treatment. 
(Sal (28) vs L-DOPA (28); F5, 60 = 48.84, p<0.0001, figure 4). Prolonged L-DOPA treatment had a 















































































* * * * * * * *
* * * *
* * * *
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Figure 4: Shows the amount of time spent by the animals in the target quadrant during the test day of 
the MWMT (n=11 per group). 
 
3.4 Prefrontal cortex tumour necrosis factor-alpha concentration 
TNF-α concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), Sal  
(28), 6-OHDA (28), and L-DOPA (28), figure 5. There was a 6-OHDA effect on TNF-α concentration 
(Sal (14) vs 6-OHDA (14); F5, 12 = 8.074, p=0,0472, figure 5) and (Sal (28) vs 6-OHDA (28); F5, 12 
= 8.074, p=0,0274, figure 5). The 6-OHDA effect was attenuated following 28 days of L-DOPA 
treatment (6-OHDA (28) vs L-DOPA (28); F5, 12 = 8.074, p= 0.0302, figure 5). 

























































































Figure 5: Graph showing PFC TNF-α concentration in the following groups: Sal (14), 6-OHDA (14), 
L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group).
3.5 Plasma corticosterone concentration 
Plasma corticosterone concentration was assessed in the following groups: Sal (14), 6-OHDA (14), L-
DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 6. The 6-OHDA lesion significantly 
increased plasma corticosterone concentration (Sal (14) vs 6-OHDA (14); F5, 12 = 45.5, p= 0,0005, 
figure 6) and (Sal (28) vs 6-OHDA (28); F5, 12 = 45.5, P<0.0001, figure 6), which was significantly 
reduced in L-DOPA treated animals (6-OHDA (14) vs L-DOPA (14); F5, 12 = 45.5, p= 0,0458, figure 
6) and (6-OHDA (28) vs L-DOPA (28); F5, 12 = 45.5, p < 0.0001, figure 6). Plasma corticosterone
concentration progressively increased in the 6-OHDA lesioned groups (6-OHDA (14) vs 6-OHDA 


































































































Figure 6: Graph showing plasma corticosterone concentration in the following groups: Sal (14), 6-
OHDA (14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
3.6 Prefrontal cortex acetylcholinesterase concentration  
AChE concentration was assessed in the ipsilateral PFC of the following groups: Sal (14), 6-OHDA 
(14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 7. There was an L-DOPA 
effect present on AChE concentration (Sal (14) vs L-DOPA (14); F5, 12 = 7.128, p= 0.0079, figure 7) 
and (Sal (28) vs L-DOPA (28); F5, 12 = 7.128, p= 0.0296, figure 7). The L-DOPA effect was also 
present when comparing the untreated and treated 6-OHDA lesioned groups after 14 days of treatment 




























































































Figure 7: Graph showing PFC AChE concentration in the following groups: Sal (14), 6-OHDA (14), 
L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
3.7 Hippocampal acetylcholinesterase concentration  
AChE concentration was assessed in the ipsilateral hippocampus of the following groups: Sal (14), 6-
OHDA (14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 8. There was a 6-
OHDA effect on AChE concentration (Sal (14) vs 6-OHDA (14); F5, 12 = 42.99, p= 0,0229, figure 8) 
and (Sal (28) vs 6-OHDA (28); F5, 12 = 42.99, p= 0,0298, figure 8). This effect persisted after L-
DOPA treatment for 14 days (Sal (14) vs L-DOPA (14); F5, 12 = 42.99, p= 0,0039, figure 8) and 28 
days (Sal (28) vs L-DOPA (28); F5, 12 = 42.99, p< 0,0192, figure 8). However, there was a L-DOPA 
effect present when comparing the untreated and treated 6-OHDA lesioned groups after 14 days of 




































































































Figure 8: Graph showing hippocampal AChE concentration in the following groups: Sal (14), 6-OHDA 
(14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
3.8 Prefrontal cortex dopamine concentration  
DA concentration was assessed in the ipsilateral PFC of the following groups: Sal (14), 6-OHDA 
(14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28), figure 9. There was a 6-OHDA effect 
on DA concentration (Sal (14) vs 6-OHDA (14); F5, 12 = 163.2, p<0,0001, figure 9) and (Sal (28) vs 
6-OHDA; F5, 12 = 163.2, P<0.0001, figure 9). This effect persisted after treatment with L-DOPA (Sal 
(14) vs L-DOPA (14); F5, 12 = 163.2, p<0,0001, figure 9) and (Sal (28) vs L-DOPA (28); F5, 12 = 
163.2, P<0.0001, figure 9). However, L-DOPA was able to attenuate the effect of 6-OHDA on DA 
concentration (6-OHDA (14) vs L-DOPA (14); F5, 12 = 163.2, p= 0,0230, figure 9) and (6-OHDA 
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Figure 9: Graph showing PFC DA concentration in the following groups: Sal (14), 6-OHDA (14), L-
DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA (28) (n=3 per group). 
 
3.9 Prefrontal cortex D1R expression   
The expression of D1R was assessed in the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), 
Sal (28), 6-OHDA (28), and L-DOPA (28), figure 10. There was a 6-OHDA effect on D1R expression 
(Sal (14) vs 6-OHDA (14); F5, 12 = 41, p<0.0001, figure 10) and  
(Sal (28) vs 6-OHDA (28); F5, 12 = 41, p<0.0001, figure 10). This effect was attenuated by 14 days 
(6-OHDA (28) vs L-DOPA (14); F5, 12 = 41, p<0.0001, figure 10) and 28 days (6-OHDA (28) vs L-
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Figure 10: Graph showing the change in D1R expression relative to GAPDH expression in the PFC of 
the following groups: Sal (14), 6-OHDA (14), L-DOPA (14), Sal (28), 6-OHDA (28), and L-DOPA 




The present study investigated L-3,4-dihydroxyphenylalanine (L-DOPA) treatment's effects on the 
learning and memory of rodents with a unilateral 6-hydroxydopamine (6-OHDA) lesion in the medial 
forebrain bundle (MFB). The present study also examined how the development of abnormal 
involuntary movements (AIMs) affect the hypothalamic-pituitary-adrenal axis (HPA axis), 
inflammation, cholinergic signalling, and dopamine (DA) signalling in unilateral 6-OHDA lesioned 
rats. The present study found that 6-OHDA lesion resulted in impaired spatial learning, spatial memory, 
and object recognition memory. The treatment with L-DOPA did not improve object recognition 
memory. However, L-DOPA treatment for 14 days improved spatial learning and memory, but spatial 
memory was impaired when the treatment was prolonged for 28 days. These behavioural changes 
observed result from increased pro-inflammatory cytokine secretion in the prefrontal cortex (PFC), 
increased plasma corticosterone concentration, reduced DA signalling in the PFC, increased cholinergic 
signalling and increased D1 receptor (D1R) expression in the 6-OHDA lesioned rats. The treatment 
with L-DOPA reduced the concentration of tumour necrosis factor-alpha (TNF)-α in the PFC, plasma 
corticosterone concentration, and D1R expression; however, increased PFC DA and 
acetylcholinesterase (AChE) concentration. Cholinergic signalling has been associated with learning 
and memory function. 
 
The novel object recognition test (NORT) is a test that uses a rodent's spontaneous preference to explore 
novel objects relative to familiar objects to assess rodent's objection recognition memory (Darcet et al., 
2014, Grayson et al., 2015, Nezhadi et al., 2016). Injecting 6-OHDA into the MFB induces impairment 
in learning and memory, suggesting that DA signalling is significant in cognitive function (Liu et al., 
2016, Du et al., 2018). The rats lesioned with 6-OHDA showed a reduced discrimination index, which 
indicates impaired object recognition memory. The above findings are similar to Bonito-Oliva et al. 
(2014)'s findings, which showed that dopamine degeneration in 6-OHDA lesioned mice resulted in 
impaired recognition memory. The above is because the interaction between the PFC and nigrostriatal 
DA projections is essential for recognition memory (Chao et al., 2013). L-DOPA exposure worsened 
and did not progressively improve recognition memory because of impaired DA signalling in the PFC. 
These findings are in line with finding from treating MitoPark mice (mice genetically engineered to 
have DA degeneration in the midbrain) with L-DOPA, resulted in recognition memory deficits assessed 
using the NORT (Li et al., 2013). Human studies showed that high L-DOPA doses worsened some 
cognitive behaviours due to PFC DA fluctuations (Gotham et al., 1988, Cooper et al., 1992, Kulisevsky 
et al., 1996).   
 
The present study further used the Morris water maze test (MWMT) to assess spatial learning and 
memory. The rats lesioned with 6-OHDA took longer to find the platform on the last day of the MWMT 
learning phase, and they spent less time in the target quadrant on test day. The above is evidence of 
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spatial learning and memory deficits in the animals lesioned with 6-OHDA. These results are in line 
with findings that showed that reduced DA signalling in hemiparkinsonian rodent model leads to 
impaired spatial learning and memory (Nezhadi et al., 2016). Furthermore, the present study indicated 
that L-DOPA improved spatial learning, although the occurrence of AIMs worsens spatial memory. 
The findings align with reports in human and animal studies showing increased DA signalling due to 
L-DOPA therapy improves spatial learning and memory (Ambrée et al., 2009, Wang et al., 2017). 
Studies have also shown that spatial learning and memory were impaired in aged rats treated with L-
DOPA (Shohamy et al., 2006, Hernández et al., 2014). Heightened inflammatory cytokines like TNF-
α have been associated with cognitive deficits that prevail in Parkinson's disease (PD), dementia, and 
Alzheimer's disease (Menza et al., 2010).  
 
Chronic inflammation is a characteristic of PD, and it has been demonstrated in animal models and 
human studies using prominent pro-inflammatory molecules like TNF-α (Menza et al., 2010). In the 
present study, the PFC of rodents lesioned with 6-OHDA had a high concentration of TNF-α, which is 
an indicator of hyper-inflammation. Studies have shown that high concentrations of pro-inflammatory 
cytokines are released by activated glial cells in response to the injection of the neurotoxin 6-OHDA  
(Lindqvist et al., 2013). The consequences of increased pro-inflammatory cytokines have been 
associated with the progressive death of DA neurons through oxidative stress and increased glutamate 
activity (Liao and Chen, 2001). The combination of heightened glutamate and oxidative stress 
exaggerates neuronal death (Liao and Chen, 2001). The pro-inflammatory environment was not 
restricted to the nigrostriatal pathway, yet it spread to other areas, including the PFC. These findings 
are supported by literature showing that oxidative stress induced by 6-OHDA injection in the striatum 
can be propagated to the PFC and the hippocampus (de Araújo et al., 2013). The heightened 
inflammatory response in the PFC was attenuated by L-DOPA treatment, which showed a reduced 
TNF-α PFC concentration. This is in line with findings that showed that treating rodents lesioned with 
6-OHDA in the striatum with L-DOPA reduced the pro-inflammatory response (de Araújo et al., 2013). 
  
One other effector for inflammation is the HPA axis's stimulation to release glucocorticoids in response 
to cell injury, stress or pathogens (Herrero et al., 2015, McHugh Power, 2016). The upregulated 
inflammatory response in the rodents lesioned with 6-OHDA lead to a hyperactive HPA axis which is 
evident by heightened plasma corticosterone concentration whose toxic effects have been shown to 
result in spatial learning, spatial memory, and episodic memory impairment (Miyoshi et al., 2002, 
Barnum et al., 2008, Wang et al., 2010). These results are in line with findings that showed that 6-
OHDA lesion in a rodent model results in a higher concentration of corticosterone in plasma (Hartmann 
et al., 1997, Ngema and Mabandla, 2017). L-DOPA was able to reduce the plasma corticosterone level 
caused by 6-OHDA lesion. Findings showed that increased DA signalling can result in DA mediated 
inhibition of adrenocorticotropic hormone release from the hypothalamus, which would result in 
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reduced corticosterone hormone secretion (Ulrich, 1973, Müller et al., 2007). The above contributed to 
improved spatial learning and memory caused by treating the 6-OHDA lesioned rodents with L-DOPA; 
however, episodic memory was still impaired, showing that there is another pathway involved in 
cognition affected. 
 
Parts of the limbic system involved in cognitive function include the hippocampus and the PFC 
(Toyoda, 2018). DA and acetylcholine (ACh) signalling have an inverse relationship and a reduced DA 
signalling that occurs in the prefrontal cortex of PD patients and rodent models would result in 
heightened ACh signalling (Maiti et al., 2017). ACh is a neurotransmitter that plays a critical role in 
learning and memory formation (Ngoupaye et al., 2018). They are two parameters that regulate ACh 
signalling: ACh receptors and AChE (Kawaguchi et al., 1995, Zhou et al., 2002). In this current study, 
rodents treated L-DOPA had augmented AChE concentration in the hippocampus and PFC which is 
necessary to reduce ACh neurotransmission by breaking down ACh to acetate and choline (Zaretsky et 
al., 2016). Increased AChE is associated with impaired object recognition memory impairment because 
of increased ACh breakdown (Ngoupaye et al., 2018). L-DOPA treatment reduced the heightened 
AChE concentrations caused by the 6-OHDA injection into the MFB. However, this treatment was not 
enough to return the AChE concentration to normal, and as the treatment continued to the LID phase, 
there is a progressive increase of AChE content in the PFC. This heightened AChE concentration in the 
PFC may be the reason for episodic memory deficits in the L-DOPA (14) and L-DOPA (28).   
 
The dentate nucleus of the hippocampus also received DA from the substantia nigra (via the mesolimbic 
pathway) and ventral tegmental area (VTA) (Nezhadi et al., 2016). Impairing DA neurotransmission in 
the substantia nigra will affect DA signalling, affecting ACh signalling in the hippocampus (Branchi et 
al., 2008). In the present study, rodents lesioned with 6-OHDA had a significantly higher AChE 
concentration in the hippocampus an indicator of hyperactive cholinergic signalling resulting from 
reduced DA signalling due to the 6-OHDA lesion (Soreq, 2015). Increased AChE activity in the 
hippocampus is associated with impaired spatial learning, spatial memory, and episodic memory 
impairment because of increased ACh signalling termination (Ngoupaye et al., 2018). L-DOPA 
treatment increased AChE concentration in the hippocampus leading to decreased ACh signalling 
(Sriraksa et al., 2012). It seems L-DOPA alleviates some cognitive deficits but impairs those that depend 
on an intact basal ganglion due to abnormal DA signalling in the striatum. 
 
DA regulates essential cognitive functions through DA receptors expressed in the prefrontal cortex 
(PFC), striatum and hippocampus (Cools et al., 2002, Da Cunha et al., 2002). The Cognitive deficits in 
PD are thought to arise from two mechanisms: reduced DA signalling in the PFC and an imbalance in 
the corticostriatal circuits (Monchi et al., 2004). The injection of 6-OHDA into the MFB reduced DA 
concentration in the ipsilateral PFC. This finding is aligned with findings showing that the 6-OHDA 
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lesion in the MFB reduced DA concentration (Adu and Mabandla, 2019, Wu et al., 2019). Treatment 
with L-DOPA increased DA signalling in the PFC, and this increased DA signalling played a role in 
ameliorating the spatial learning and memory impairments that persisted due to the 6-OHDA lesion  
(Chiu et al., 2015). DA signalling is dependent on DA receptors expression (Ryoo et al., 1998). The 
hypoactivation of D1Rs in the PFC can impair cognitive function in Alzheimer's disease, Schizophrenia, 
and PD (Floresco and Magyar, 2006, Kintz et al., 2017, Meltzer et al., 2019). In the present study, there 
was increased D1R expression in the PFC of rats lesioned with 6-OHDA because of the reduced DA 
concentration in the PFC. These findings align with reports showing that 6-OHDA lesion leads to 
reduced DA concentration in the PFC and in response to the DA depletion the PFC post-synaptic 
neurons increase the expression of dopamine receptors like D1R (Cools, 2006, Kravitz et al., 2012). 
The treatment with L-DOPA increases DA concentration in the PFC (Frank, 2005) , which causes a 
reduced dopamine receptor expression, as seen in the present study.   
 
5. Conclusion 
The findings of the present study showed that a 6-hydroxydopamine (6-OHDA) lesion in the medial 
forebrain bundle (MFB) impairs recognition memory and although L-3,4-dihydroxyphenylalanine (L-
DOPA) improved spatial learning and memory, it was not able to enhance object recognition memory. 
L-DOPA can reduce imbalances in the hypothalamic-pituitary-adrenal axis, neuroinflammation in the 
prefrontal cortex (PFC), but not the heightened cholinergic signalling in both the hippocampus and 
PFC, and it maintained DA signalling in the PFC. The death of dopamine (DA) neurons in the MFB 
significantly reduced DA signalling and increased neuroinflammation in other brain areas that play 
crucial roles in cognition. Future studies may focus on other brain areas involved in learning, memory 
function, and the interactions those brain areas have with the basal ganglia. 
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Chapter 4: Synthesis 
Parkinson's disease (PD) is characterised by abnormal motor symptoms like postural instability and 
akinesia. However, PD patients also display non-motor symptoms like cognitive decline. These 
symptoms result from the death of dopamine (DA) neurons in brain areas collectively called the basal 
ganglia (BG). The BG is responsible for initiating and halting movement. In PD, some dysfunctions 
begin in the BG and spread to other brain areas via direct or indirect communication with the BG. The 
brain areas affected include the cerebellum, prefrontal cortex (PFC), hippocampus, amygdala, and other 
brain areas. Literature has shown that L-3,4-dihydroxyphenylalanine (L-DOPA) can alleviate motor 
symptoms of PD and some cognitive deficits by increasing DA signalling in the brain. However, the 
long-term use of L-DOPA is known to result in abnormal involuntary movements called L-DOPA 
induced dyskinesias (LIDs). Therefore, it became necessary to explore the effects that the development 
of LIDs would have on motor incoordination and cognitive decline experienced by PD patients.  
 
The aid used to explore LIDs development's effects was a 6-hydroxydopamine (6-OHDA) model, 
resulting in LIDs-like behaviour when the rats are treated with L-DOPA. The present study showed that 
L-DOPA could alleviate motor incoordination, spatial learning, and spatial memory, but failed to ease 
object recognition memory. LIDs-like behaviour development in rodents leads to hypokinesia and 
impaired spatial memory. Altered behaviour is usually the result of impaired signalling in the brain and 
the case of PD, many of abnormalities stem from the death of DA neurons in the BG. L-DOPA slightly 
increased DA signalling, but even with this exogenous intervention, the brain progressively increased 
DA receptor expression to compensate for the significantly lower DA signalling. This is thought to play 
a crucial role in the progressive development of LIDs. The low BG DA signalling caused a reduced 
PFC DA concentration, which leads to reduced DA receptor activation is associated with impaired 
spatial learning, impaired spatial memory, and impaired object recognition memory. L-DOPA therapy 
improved spatial learning and memory. However, this changes as LIDs-like behaviour occurs because 
the continued exposure to exogenous DA will eventually lead to a reduced DA receptor expression in 
the PFC, which has been associated with a severe decline in working memory. 
 
Along with DA signalling deficiencies, increased termination of cholinergic signalling in the brain 
underlies the cognitive impairments in PD. The present study found that in the two limbic brain areas 
that play a significant role in learning and memory had a higher concentration of the enzyme 
acetylcholinesterase (AChE) in groups treated with L-DOPA. This enzyme terminates cholinergic 
signalling, and other studies have shown that a high concentration of AChE in the hippocampus and 
PFC causes impaired object recognition memory. Most studies have focused on impaired DA signalling 
in the BG. Still, the present study also looked at other molecular alterations in different brain areas that 




The uncontrolled death of DA neurons causes a pro-inflammatory response. While this initiative is 
beneficial, this response's continued stimulation due to continued tissue damage has neurotoxic 
consequences. One such consequence is oxidative stress when reactive oxygen molecules break down 
the cell membrane and eventually kill the cell. The present study found that hyper-inflammation persists 
in the BG of the untreated brain and spreads to other brain areas like the cerebellum and the PFC. The 
neurotoxic effects of hyper-inflammation could be why some PD patients present with cognitive deficits 
even in the early stages of the disease. L-DOPA reduced the inflammatory response in the indirectly 
affected brain areas although after LIDs-like behaviour developed, there was hyper-inflammation in the 
cerebellum. In addition to oxidative stress, another consequence of hyper-inflammation is the 
stimulation of the hypothalamic-pituitary-adrenal (HPA) axis. This may increase the neurotoxic 
environment since the hyperactivation of the HPA axis results in an increased secretion of 
glucocorticoids, i.e., corticosterone (rodents) and cortisol (humans). Heightened glucocorticoids 
concentration is neurotoxic and has been associated with impaired spatial learning, impaired spatial 
memory, and impaired episodic memory. L-DOPA was able to reduce the plasma corticosterone level 
and therefore ameliorating imbalance caused by the heightened inflammation. 
 
Conclusion  
The present study showed that the dopamine (DA) replacement therapy with L-3,4-
dihydroxyphenylalanine (L-DOPA) attenuated the hypokinesia, impaired motor coordination, impaired 
spatial learning, and spatial memory caused by the injection of 6-hydroxydopamine (6-OHDA) into the 
medial forebrain bundle. The progressive increase in the expression of D2 receptor (D2R) and the 
persisting hyper-inflammation in the BG seem to play a vital role in the development of L-DOPA 
induced dyskinesias (Mela et al., 2012, Suarez et al., 2016, Pisanu et al., 2018). Neuroinflammation 
makes the DA neurons vulnerable and increases the chance of degeneration. The high concentration of 
DA resulting from L-DOPA helps with the motor symptoms; however, the eventually increased 
expression of D2R receptors seem to increase the likelihood of abnormal involuntary movement (AIMs) 
development. The death of DA neurons in the medial forebrain bundle significantly reduced DA 
signalling and increased neuroinflammation in other brain areas that play crucial roles in cognition. 
However, L-DOPA can reduce imbalances in the hypothalamic-pituitary-adrenal axis, 
neuroinflammation in the PFC, but cholinergic signalling in both brain areas was significantly impaired 
during AIMs. This resulted in impaired episodic and spatial memory deficits. Furthermore, these 
cognitive deficits may be caused by dopamine influx to cortical areas related to these particular 
cognitive functions  (Swainson et al., 2003, Ko et al., 2016). Future studies may focus on the progressive 
alteration of apoptotic markers in the cerebellum, thalamus, and motor cortex to elucidate the 
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